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ABSTRACT 
 
Study 1:  A retrospective analysis of the effects of hCG and deslorelin on the reproductive 
efficiency on two commercial horse farms.  
 
Reproductive data from two central Illinois horse farms was analyzed to compare the 
effectiveness of hCG (Chlorulon™) and a sustained release implant formulation of deslorelin 
(Ovuplant™) for inducing ovulation and their overall effect on reproductive efficiency. Data 
were collected over 3 consecutive years, from 1999-2001; a total of 1422 cycles were examined 
from 658 mares. Of the 1422 cycles examined, 383 were treated with hCG, 451 with deslorelin 
and 583 cycles were untreated.  Mares in this study were over 2.1 times more likely to become 
pregnant if ovulation was induced (p<.001).  Mean days to ovulation was significantly shortened 
by using hCG or deslorelin compared to no treatment for all follicle sizes except those >45 mm 
(p=.001).  Time from treatment to ovulation was affected by follicle size at time of treatment and 
by treatment given.  When treatment was given at follicle sizes from 35 mm-39 mm, time to 
ovulation was shorter with deslorelin (2.02 days) than with hCG (2.68 days) (p=.000).  The 
number of palpations was not decreased by the use of ovulation induction but follicle size at 
administration and day of administration showed a positive effect on reducing the number of 
palpations.  Administration of either agent at the first breeding examination when follicles were 
less than 35 mm in diameter decreased the number of palpations per cycle by one in comparison 
to non-treated mares. (p=.009)  Fewer artificial inseminations per cycle were performed using 
deslorelin for follicles between 35 and 44 mm compared no treatment [35-39 mm follicles 
(p=.000): deslorelin 1.21 AI, untreated 1.39 AI; 40-44 mm follicles (p=.000): deslorelin 1.16 AI, 
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untreated 1.48 AI] . Administration of either hCG or deslorelin to mares possessing a <35 mm 
follicle at the first breeding exam decreased the number of artificial inseminations required per 
cycle by 1 (p=.001). Both agents performed equally well at inducing ovulation within 48 hours 
of administration.  Deslorelin appeared more consistent in decreasing the days to ovulation in 
comparison to hCG .  Deslorelin decreased the days to ovulation at <35 mm follicles 
(p=.001)[deslorelin, 2.34 days, hCG 2.57days, untreated 3.54days], 35-39 mm follicles (p=.000) 
[deslorelin 2.02 days, hCG 2.68 days, untreated 3.87 days] and 40-44mm follicles (p=.000) 
[deslorelin 2.10 days, hCG 2.47 days, untreated 3.49 days] ,  Human chorionic gonadotropin 
only decreased the days significantly on follicles sized between 35-39 and 40-44 mm.  Deslorelin 
also significantly decreased the days to ovulation over hCG at follicles sized between 35-39 mm.  
Use of these agents in a commercial breeding setting appears to be of value for improving 
pregnancy rate and decreasing the time to ovulation for improved timing of insemination.  
Management of the estrus cycle of the mare will determine if ovulation induction decreases the 
number of palpations and artificial inseminations per cycle.  Management schemes must be 
considered in evaluating effectiveness of ovulation induction drugs since time of administration 
within the cycle and size of follicle at administration appear to affect reproductive efficiency. 
 
 
 
 
 
Study 2: Effect of deslorelin sustained release implants on the interovulatory period and response 
to PGF2  administration 6 days after ovulation 
 
Ovuplant™ is a sustained release implant that contains the gonadotropin releasing 
hormone (GnRH) agonist deslorelin.  Subcutaneous administration to a mare during estrus will 
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induce ovulation within 48 hours.  Clinical evidence suggests that Ovuplant™ causes an increase 
in the interovulatory period of mares not conceiving on the treated cycle. A down regulation of 
the hypothalamic pituitary axis is thought to be the main cause of the increased interovulatory 
interval but no investigation has occurred concerning the function of the corpus luteum formed 
by ovulation induction by Ovuplant™.  This study was performed using six teaching mares at the 
University of Illinois Veterinary Teaching Hospital in a cross over design clinical trial with four 
treatment cycles: a control (untreated cycle), a natural cycle with luteolysis induced with 
prostaglandin F2 alpha (PGF2α), a cycle with ovulation induced with Ovuplant™, and a final 
cycle with ovulation induced with Ovuplant™ and luteolysis induced with prostaglandinF2alpha 
(PGF2α).  Progesterone levels for assessment of corpus luteum function were determined every 
three days during the diestrus period and days between ovulations on each treatment cycle 
determined the interovulatory period.  The goals of the study were to determine the effect of 
Ovuplant™ administration on the interovulatory period, to examine the progesterone production 
of the corpus luteum formed after ovulation induction with Ovuplant™, and to determine the 
response of the corpus luteum formed by Ovuplant™ to induced luteolysis.     
Progesterone levels differed between control mares and mares induced to ovulate with 
Ovuplant and administered prostaglandin 6 days after corpus luteum formation (p=.02).  The 
interovulatory periods of mares treated with Ovuplant™ (26.00d) did not differ significantly 
from untreated mares(21.67 days) (p=..01).  The interovulatory periods of untreated mares 
administered prostaglandin (11.8 days) differed significantly from those treated with Ovuplant™ 
(26.00 days) (p=.01).  Four mares treated with Ovuplant™ experienced delayed returns to estrus 
of 3-25 days.   Ovuplant™ did not induce a corpus luteum which differed in progesterone 
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production or its ability to respond to PGF2α.   Ovuplant™ appears to extend the interovulatory 
period of sensitive mares.   
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CHAPTER 1 
INTRODUCTION 
 
A major objective for horse breeders is to inseminate a desired number of mares in a 
minimum amount of time with the majority of mares becoming pregnant and birthing a live foal 
the following spring (Pickett and Voss, 1999).  Economic considerations require this to be 
accomplished as inexpensively as possible.  Synchronization of ovulation with the placement of 
an adequate amount of viable spermatozoa is critical to obtain both of these objectives.  
Ovulation induction agents can assist in attaining this synchrony and may also decrease the cost 
and physical effect of breeding especially when considering the use of transported semen and 
natural breeding. 
There are currently three types of ovulation induction agents available for use in the 
mare: human chorionic gonadotropin (hCG), gonadotropin releasing hormone (GnRH) agonists, 
and recombinant luteinizing hormone (LH).  The two commercially available, commonly used 
agents today are hCG (Chorulon™) and deslorelin, a GnRH agonist, available in an injectable 
form (SucroMate™, Bioniche Life Sciences Inc.) or a slow release implant (Ovuplant™, Fort 
Dodge Animal Health/Peptec).  Ovuplant™ was the first available preparation of deslorelin and 
was released for commercial use in 1998 by Fort Dodge Animal Health.   
Both agents have their limitations.  Human chorionic gonadotropin has often failed to 
induce ovulation after being administered to the same mare multiple times.  This is especially 
noticeable when given to the same mare within the same breeding season (Roser et al, 1979; 
Voss et al, 1975; McCue et al, 2004).  Being a large protein, human derived hormone, it has also 
induced hypersensitivity reactions in mares. (Roser et al, 1979; Voss et al, 1975)  In the search 
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for a more reliable agent, deslorelin was developed and first released in the form of a slow 
release implant called Ovuplant™.  (Jochle and Trigg 1994)  Ovuplant™ was well received in 
the 1998 breeding season as it displayed consistent ovulation induction even when administered 
repeatedly to the same mare.  (McKinnon et al, 1993; Ganheim et al, 1995; Samper et al, 2002)  
By the end of the 1998 breeding season and into the 1999 breeding season, increased 
interovulatory intervals in mares treated were being observed. (Vanderwall et al, 2001; 
Morehead et al, 2000)  Mares that were slow to return to heat when not pregnant was considered 
a costly inconvenience especially if the mare foaled late in the year (further delaying or 
disallowing her rebreeding for that season) or was an embryo donor mare (decreasing the number 
of embryos that could be retrieved leading to a decrease in profitability).  Many mares failed to 
return to estrus for months. (McCue et al, 2002) 
Control of gonadal function arises at the level of the hypothalamus and pituitary within 
the brain although other factors, such as light stimulus and melatonin, affect cycling in mares.  
Reasons for a delayed return to estrus could be attributed to anything affecting this 
hypothalamic-pituitary-gonadal axis.  Research into the cause of the delayed return to estrus 
induced by Ovuplant™ was pursued and it centered on the effect of this GnRH agonist on the 
hypothalamic-pituitary axis of the mare. (Johnson and Thompson Jr. 2000; Porter and Sharp, 
2002)  Earlier clinical trials using Ovuplant ™ noted clinical symptoms indicative of receptor 
down-regulation at the level of the pituitary (increases in the duration of estrus due to the delayed 
growth of large follicles, increased interovulatory intervals, increasing LH levels with decreasing 
FSH levels) when the amount of deslorelin administered was increased to 5-10 times the 
minimally effective dose. (Jochle and Trigg 1994)  No research evaluated the effect of 
Ovuplant™ on the gonad and specifically the possibility of prolonged or abnormal function of 
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the corpus luteum (CL) formed upon induction of ovulation by Ovuplant™, as a cause of the 
increased interovulatory interval.  (Ginther, 1990) 
The goals of this project were to examine the effectiveness and efficiency of using 
ovulation induction agents when breeding mares in an uncontrolled, clinical setting and to 
examine the effect the Ovuplant™ form of deslorelin may have on luteal retention and function 
in a controlled clinical trial.  
For Study 1, reproductive data was collected from 2 central Illinois horse farms and 
analyzed retrospectively to compare the effect of the two most commonly used ovulation 
induction agents, hCG (Chlorulon
™
) and deslorelin (Ovuplant
™
) on mare reproduction when 
compared to no treatment.   The data was analyzed to determine if pregnancy rate, number of 
palpations, and number of artificial inseminations (AIs) were affected by giving either of the two 
induction agents.  The two agents were assessed for their effectiveness at different follicle sizes 
to reduce the number of days to ovulation in comparison to untreated mares.  Each drug’s ability 
to induce ovulation within 48 h of administration in a field setting as per label claim was 
assessed.   The data was also explored to define if early administration of an induction agent 
within the breeding cycle may be beneficial for reducing the days to ovulation. 
For the controlled study examining the effect of deslorelin, specifically the Ovuplant™ 
formulation, on the function of the CL post-ovulation induction, six teaching mares housed at the 
University of Illinois Veterinary Teaching Hospital were utilized.  A cross over clinical trial 
design was used to examine the mares through an untreated estrus, an estrus induced with 
Ovuplant™, and an estrus induced with Ovuplant™ followed by prostaglandinF2 alpha 
(PGF2α).  Days between ovulations were counted to determine the interovulatory interval and 
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progesterone sampling allowed for assessment of CL function. An increased interovulatory 
interval was determined by the number of days from one ovulation to the next exceeding the 
expected number of days determined by the untreated cycle.  CL function was examined by 
determining the progesterone levels during the diestrus phase of the cycle for each mare and for 
each cycle studied.  Both experiments are detailed in the Materials and Methods section.   
The mare’s estrous cycle is controlled by several extraneous factors, most notably light, 
and is subject to aberrations from both internal and external influences.  The normal estrous 
cycle as well as follicle growth, ovulation and luteolysis and the factors which can influence 
normalcy are explored in the literature search.  Detailed descriptions of pertinent hormones 
involved in this study and the available ovulation induction agents will be imparted.  A 
description of the GnRH receptor of the mare and a discussion of its function will finalize the 
literature search. 
Study 1 will show that ovulation induction agents do appear to improve reproduction 
efficiency when breeding mares especially in regards to pregnancy rate and both the agents 
discussed appear equal in their effect at inducing ovulation and shortening the estrus period.  
Both agents appear to have their advantages and the results allude to the conclusion that there are 
more opportune times within the estrus period to utilize ovulation induction.  An elaboration of 
the concluded points, the best utilization of ovulation induction agents, and the limitations of this 
study are found within the discussion.  
Study 2 will show that deslorelin in the sustained release formulation (Ovuplant™) did 
prolong the interovulatory interval of some of our study mares but there appeared no influence 
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on the function of the corpus luteum formed by Ovuplant™.  The conclusions drawn and the 
shortcomings of the study will be deliberated in the discussion section.    
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CHAPTER 2 
  LITERATURE REVIEW 
 
2.1 Unique Anatomy of the Mare’s Ovary 
In comparison to other domestic mammals, the mare’s reproductive tract has some 
unusual features, which may influence our ability to control her cycle and improve reproductive 
efficiency.  Two of the most striking differences are the shape and structure of the ovary.  The 
ovaries of the mare are kidney shaped (reniform) and have a distinctive ovulation fossa. 
(Witherspoon, 1971)  At birth, the equine ovary’s structure is similar to other domestic species.  
At or near puberty, the ovary changes from a symmetrical bulbous structure to the more kidney 
shaped mass of the sexually mature adult. The germinal tissue (cortical tissue), originally 
exterior, assumes an interior position with a peripheral collagenous connective tissue casing 
(medullary tissue) where the vascular supply is found.  The cortex of the ovary only reaches the 
surface of the ovary at the ovulation fossa and ovulation can only occur at this area. (Adams et 
al., 1988; Stabenfeldt et al, 1975)  This inverted structure can become confusing during rectal 
exams as developing follicles are difficult to palpate manually and a mature corpus luteum (CL) 
is non-palpable.  The ovaries of the mare are also very large in comparison to many other 
domestic mammals measuring 5-8 cm in length, 3-5 cm in height, and 2-3 cm in width for most 
light horse breeds.  With these large ovaries come uniquely large pre-ovulatory follicles 
measuring on average 45 mm at ovulation.  (Witherspoon, 1971)  This is much larger than the 
preovulatory follicles of other domestic hoof stock such as the cow (11-16mm) and ewe (5-
8mm). (Driancourt, 1991) 
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2.2 Normal Estrous Cycle of the Mare 
The estrous cycle of the mare can be divided easily into a follicular phase and a luteal 
phase as per other  domestic species and is typically defined as the period from one ovulation to 
the subsequent ovulation when accompanied by signs of estrus and /or progesterone levels below 
1ng/ml of plasma.  (Hughes et al, 1975; Stabenfeldt et al., 1971)  During the “true”, or 
physiologic, breeding season, the estrous cycle averages 21-22 days with an average duration of 
estrus of 5-7 days and diestrus 15-16 days.  Unlike other domestic species such as the cow, ewe 
and doe which display much more consistency in cycle length, estrous cycle length in the mare 
can vary considerably ranging from 13-34 days depending on the mare and season (Hughes et al, 
1977).  In the northern hemisphere, most mares will be cycling normally by the month of May 
and will continue to cycle for approximately 155 days. (Adams et al, 1988; Witherspoon, 1971; 
Ginther et al, 1972)   
Mares are seasonally polyestrous with regulation of cyclicity coming primarily from 
photoperiod, with other factors such as nutrition and climate (mainly temperature) contributing 
to a lesser degree (Adams, 1988; Ginther et al, 1974; Hughes et al, 1977).  These factors also 
contribute to the variability in the length of the estrous cycle noted between mares. As a mare 
progresses into the physiologic breeding season with increasing daylight, the length of estrus 
significantly decreases while the length of diestrus increases while the overall length of the 
estrous cycle remains unaltered.  (Ginther et al, 1972)  Considerable variation though is noted in 
the length of estrous between mares, between different breeds and between different seasons of 
the year.  (Stabenfeldt et al, 1975)  Much of the variation is noted in the length of the follicular 
phase and is related to season (primarily the photoperiod effect).  Genetic factors (breed) appear 
also to play a minor role in influencing the length of the follicular phase.  The diestrus phase of 
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the estrous cycle appears to remain most constant in duration amongst mares with photoperiod 
and season imparting minor effects.  (Adams et al, 1988; Witherspoon, 1971; Ginther et al, 1972)   
Interestingly though, individual mares consistently either display a short or long estrus (Hughes, 
1980) with the length of estrus more repeatable within mares than the length of diestrus.   
 
 2.3 Control of the Estrous Cycle:  The Hypothalamic-Pituitary-Gonadal Axis 
Regulation of reproduction in the mare is mainly via photoperiodic control of the 
hypothalamic-pituitary-gonadal axis although temperature and nutrition also play a role. (Adams, 
1988; Ginther et al, 1974; Hughes et al, 1977)  This is similar to other domestic species such as 
the ewe except ewes cycle during times of short photoperiod and mares cycle during times of 
long photoperiod.  The exact mechanisms of control for the mare estrous cycle have not been 
fully established.  A unique interaction between the nervous system and the endocrine system, 
the hypothalamus and the pituitary gland, provides the platform for regulation.  (Ginther, 2012)  
Control begins with perception of light by the retina of the eye.  Via the nervous system, this 
signal is transmitted to the pineal gland within the brain.  The pineal gland transforms the 
nervous signal into an endocrine signal with the production of melatonin.  Melatonin is 
synthesized and released during dark periods.  Melatonin acts upon the hypothalamus to produce 
and stimulate the release of gonadotropin releasing hormone (GnRH).  The release of GnRH 
initiates cyclicity in the short day breeders.  In the mare, the opposite is true: GnRH is released 
and cyclicity occurs in response to low levels of melatonin. 
The hypothalamus, designated the control center for reproductive hormones, lies within 
the brain and is comprised of groups of nerve cell bodies.  These neurons produce the hormone 
called GnRH which is the primary releasing hormone of reproduction.  Neurons from the 
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hypothalamus communicate with the pituitary gland, specifically the anterior pituitary gland, via 
a unique aspect of the circulatory system called the hypothalamo-hypophyseal portal system. 
(Ginther, 2012)  GnRH, via this portal system, stimulates the release of the anterior pituitary 
hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH).  FSH and LH act 
upon the gonads of the mare to stimulate follicular growth and ovulation.  FSH stimulates 
follicular growth and maturation leading to the production of the steroid hormone estrogen.  
(Donadeu and Watson, 2007) LH induces ovulation of the dominant follicle and formation of the 
corpus luteum (CL) leading to the production of the steroid hormone progesterone.  These two 
steroid hormones, along with several other peptide, protein and glycoprotein hormones, act to 
further control reproduction via positive and negative feedback loops to the hypothalamus, 
pituitary, and the gonads themselves.   
Onset of the mare estrous cycle is associated with the stimulus of long light periods and 
artificial manipulation of light has for many years been utilized by the equine industry to 
advance the physiologic breeding season.  A transitional period from anestrus to estrus cycling, 
characterized by irregular and anovulatory estrus cycles, occurs in mares whether manipulating 
the cycle with artificial lighting or not.   Artificially manipulating the mare’s estrous cycle does 
not negate transition or the effect it has on the hormone and receptor levels within the 
hypothalamus and anterior pituitary. (Hart et al, 1984; Silvia et al, 1986; Donadeu and Watson, 
2007)  Understanding that there are changes in the hormones and their receptors during the 
spring transition phase as well as the physiologic breeding season is important when managing 
mares for maximal reproductive efficiency.  Follicular development patterns are different in the 
early spring months and these follicles respond differently to ovulation induction agents partially 
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due to the incompetence of the hypothalamic-pituitary axis. (Silvia et al, 1986; Donadeu and 
Watson, 2007)   
 
2.4 Follicular Growth  
Mares have a very effective follicle selection mechanism.  They, along with cows, have 
the lowest incidence of multiple ovulations, and hence multiple fetuses, of the farm animal 
species. (Ginther, 2000)  Follicular waves develop in the mare during the second half of an 
estrous cycle and typically culminate in the ovulation of one follicle.  Double ovulations can 
occur and are affected by season, age of the mare, breed, and pharmacologic manipulation of the 
estrous cycle.  Near the peak of the physiologic breeding season, double ovulations can occur in 
approximately 25-26% of estrous cycles. (Hughes et al, 1977)  The incidence of double 
ovulations in the pony mare is reportedly rare. (Ginther et al, 1972)   
 Mares develop both major and minor follicular waves, as in other farm animal species, 
but a single major wave is most commonly associated with the estrous cycle of the mare. A 
major wave is characterized by the divergence of a follicular wave into subordinate and a 
dominant follicle(s), which may ovulate while the subordinate follicles regress.  A minor wave is 
characterized by a follicular wave which never forms a designated dominant follicle. 
Considerable breed variation exists in wave patterns.  Pony mares and quarter horses usually 
develop one major wave in late diestrus culminating in an ovulation.  In contrast, thoroughbreds, 
related warm-blood breeds, and Standardbred mares are considered to have a higher double 
ovulation rate as they often develop a secondary major wave in early diestrus with the dominant 
follicle regressing or ovulating. (Hughes et al, 1980; Ginther, 2000)    
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Mares that have a major secondary wave develop in late estrus or early diestrus can 
produce a dominant follicle, which can ovulate, resulting in a diestral or secondary ovulation, or 
produce an anovulatory dominant follicle, which regresses.  Diestrus ovulations are defined as 
ovulations occurring under the influence of high progesterone.  This phenomenon of diestrus 
ovulations is unique to the mare.  (Hughes et al, 1977; Ginther, 1974; Stabenfeldt et al, 1975)  
These ovulations produce fertilizable oocytes but typically do not result in pregnancy unless the 
ovulation closely follows an ovulation of the primary major wave when semen may still be 
present in the track. These secondary major waves can affect reproductive efficiency since a 
functional CL formed by the secondary ovulation may affect the mare’s expected return to estrus 
increasing the interovulatory interval. (Ginther, 1990)   
 
2.5 Follicular Dynamics, Ovulation, & Luteolysis in the Mare 
Stimulation of a follicular wave occurs via a surge of FSH in the mare just as in other 
domestic farm animal species although the resulting sizes of the follicles are notably larger. 
(Witherspoon, 1971)  Wave emergence begins with the appearance of one of two 6mm follicles 
with numerous others joining the wave over about a 3-4 day period.  One of these initial follicles 
will typically remain slightly larger and end as the dominant or ovulatory follicle.  These 
emerging follicles undergo a period of simultaneous growth, under the influence of FSH, 
growing at a common rate of about 2-3mm/day until the largest follicles reach a size of about 
22mm, typically  about 7 days prior to ovulation.  At the same time, FSH levels peak and LH 
levels begin to increase and three days after the peak, deviation occurs.  Deviation occurs when 
one or two of the largest follicles continue to grow at the 2-3mm/day rate while all the smaller, 
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subordinate follicles become static in growth and regress.  The largest or dominant 
follicle(s),continue to grow until an LH surge initiates ovulation. (Ginther, 1992; Ginther, 2000) 
Follicles control deviation through the inhibition of FSH release. During wave 
emergence, FSH drives the growth of the follicles and peaks when the follicles are about 13mm 
in diameter. The decline in the concentration of plasma FSH at this time is a function of the 
larger follicles of the wave producing inhibin within their granulosa cells which suppresses FSH 
release from the hypothalamus.  (Gastal, Gastal, Wiltbank et al, 1999)  Receptors within the 
larger follicle(s) switch to become more LH responsive for growth (vs. only FSH responsive) 
making LH critical to the continued growth of the dominant follicle.  After deviation, continued 
suppression of FSH activity becomes the sole responsibility of the dominant follicle. (Donadeu et 
al, 2001)  With deviation comes a rapid increase in the production of estradiol by the granulosa 
cells of future dominant follicle.  (Donadeu et al., 2001; Gastal, Gastal, Wiltbank et al, 1999)   
Uterine edema is noted on ultrasound examination as the estrogen level raises.  Behavioral signs 
of estrus will characteristically begin shortly after this point as will a greater responsiveness to 
FSH and LH by the developing dominant follicle.  (Gastal et al, 1999; Ginther, 2000; Ginther, 
2003)   LH suppression at this point in the cycle will cause restricted growth of the dominant 
follicle(s).  (Ginther et al, 2003)  It is an interesting point that LH plays a critical role in the both 
the growth and maturation of the dominant follicle as well as its ovulation and luteinization. 
The pre-ovulatory dominant follicle grows at a rate of approximately 3mm in diameter a 
day up to 35mm about four days before ovulation.  At this point it enters the pre-ovulatory period 
when the follicle begins a more rapid growth rate plateauing approximately two days before 
ovulation at about 40-50mm in diameter.  As estrogen levels reach higher concentrations near the 
end of the follicular phase, follicles acquire the LH receptors needed for ovulation to occur.  
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(Ginther, 1992)  At two days prior to ovulation, follicular growth becomes static and estradiol 
peaks. As estradiol peaks and begins to drop, any negative effects on LH secretion are removed 
allowing for a more rapid release of LH.  However, the rise of LH is anything but rapid in the 
mare as she is unique in her prolonged LH surge which occurs over a period of several days.  
(Geschwind et al, 1975)   At the time of estradiol peak two days prior to ovulation, the negative 
influence on FSH is removed causing FSH secretion to resume and a new cohort of follicles 
begins to grow. (Ginther, 1992)   As ovulation and luteinization of the once dominant follicle 
occurs, progesterone levels rise having a negative influence on LH levels leading to the peak and 
drop of LH one day post ovulation. (Ginther, Gastal et al., 2008)  This is also unique to the mare. 
After the induction of ovulation has occurred, formation of the corpus luteum (CL) 
begins with morphologic changes within the granulosa cells of the collapsed follicle which allow 
for a switch from producing estrogen to producing progesterone.  This process is called 
luteinization and involves the transformation of the theca interna cells and granulosa cells of the 
ovulating follicle into luteal tissue.  Granulosa cells become large luteal cells which contain 
receptors for PGF2 α hence mediating the luteolytic cascade and the theca interna cells become 
small luteal cells which are responsive to LH in their production of progesterone.  Both types of 
cells contribute to the production of progesterone from the corpus luteum. (Niswender et al, 
2000)   Production of progesterone rises significantly in 12 hours (Plotka et al, 1975) and usually 
measure greater than 2 ng/ml in the plasma by 48 hours post ovulation (Townson et al, 1989; 
Koskinen et al, 1990).   Morphogenesis becomes complete in about 5-6 days post-ovulation and 
the corpus luteum is fully functional in its production of progesterone at that time.  The 
progesterone levels begin to drop around day 14 post ovulation if the mare fails to become 
pregnant. (Short, 1959) 
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2.6 Hormonal Control of the Peri-ovulatory Period and Luteolysis 
Near the end of the luteal phase (13.0±.3d), (Ginther and Beg, 2011), provided there is no 
embryo within the uterine lumen, another hormonal cascade ensues to cause lysis of the corpus 
luteum with subsequent functional regression.  The complete mechanism by which luteolysis 
occurs in the mare is as yet undefined but likely begins in a similar fashion to the ruminant 
model although an increase in estrogen from growing follicles is not required. (Ginther, 2012)   
Initially, in the mare, there is a small transitional pulse of PGFM (a prostaglandin metabolite) 
with a concurrent increase in pulsatile release of oxytocin.  The source of the oxytocin is thought 
the posterior pituitary in the cow but is yet undetermined in the mare.  Oxytocin has been 
identified in the CL of the mare but could also be released from the endometrium or posterior 
pituitary.  (Ginther and Beg, 2011)  Oxytocin triggers the episodic release of PGF2α from the 
uterine endometrium.  A positive feedback loop furthering the release of both hormones has been 
identified in the cow but all the components of a feedback loop have not been identified in the 
mare.  In the mare, PGFM stimulates increased levels of oxytocin and PGMF stimulates 
increased release of oxytocin.  (Shand et al, 2000, Ginther and Beg, 2011)  Progesterone, 
prolactin and cortisol may also play some part in luteolysis in the mare but estradiol and cortisol 
are not the initiators of the cascade. (Ginther and Beg, 2011)  Progesterone drops rapidly within 
1-2 hours after luteolysis to levels around 2ng/ml or less after which a more moderate ensues. 
(Ginther and Beg, 2011)  Loss of progesterone action in other species studied occurs due to 
down regulation of its own receptors, both in the hypothalamus and the endometrium of the 
uterus, allowing estrogen to begin to affect these tissues.  (McCracken et al, 1999)  Estrogen has 
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a positive feedback effect on the hypothalamic pituitary gonadal axis allowing follicles to grow 
and another cycle to ensue.   
 
2.7  GnRH, LH,  and Prostaglandin F2α 
GnRH (gonadotropin releasing hormone): 
Hypothalamic GnRH is a decapeptide (contains 10 amino acids) neural hormone with a 
short half-life (5 to 10 minutes).  The sequence of amino acids is (1) glutamine (2) histidine (3) 
tryptophan (4) serine (5) tyrosine (6) glycine (7) leucine (8) arginine (9) proline (10) glycine.  Its 
composition remains conserved across species.   
Synthesis occurs in the neurosecretory cells of the hypothalamus and in the horse, this 
production does not appear to be restricted to a discrete area of the hypothalamus as in other 
species, but rather appears evenly distributed throughout the hypothalamus.  GnRH axons from 
the hypothalamus pass mainly to the median eminence where the secretory product is stored in 
terminal granules. Neuron depolarization releases the stored GnRH to enter capillaries leading to 
the portal vessels that transport the hormone to the pituitary where it binds to receptors on the 
gonadotrophs.  Release occurs in picomolar concentrations in the portal blood and even smaller 
values are found (subfemtomolar) in the peripheral blood. (Ginther, 1992) 
GnRH release occurs in a pulsatile nature in the periovulatory period with secretion 
actually appearing as a continuum with broad pulses found superimposed over a tonic 
background.  Pituitary concentrations of the gonadotropes FSH and LH appear pulsatile and 
coincident with the GnRH pulses.  As determined by frequent collection of blood from the 
intercavernous sinus (allowing collection of blood relatively undiluted from the pituitary venous 
blood), 93% of the LH pulses occurred within 5 minutes after a GnRH pulse.  (Alexander and 
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Irvine, 1987).  FSH and LH pulses coincide in a nearly opposite relationship through the 
periovulatory period except near ovulation when concentrations reach similar levels. (Miller et 
al, 1980,; Alexander and Irvine, 1987) 
 
LH: 
Luteinizing hormone is the primary hormone involved in ovulation of the dominant 
follicle.  LH is a glycoprotein hormones consisting of two subunits, termed alpha and a beta.  
Different genes encode for each subunit and synthesis of each subunit occurs separately within 
the gonadotroph cell and each subunit later spontaneously associates to form the entire molecule.  
Synthesis of the beta subunit appears the rate-limiting step.  The alpha subunit appears in excess 
within the cells.  (Ginther, 1992). The alpha subunit is species specific and has essentially the 
same structure as the other glycoprotein hormones found in the horse, thyroid stimulating 
hormone (TSH) and equine chorionic gonadotropin (eCG).  The equine alpha subunit’s amino 
acid sequence differs from that of other species and this may dictate the equine gonadotropin’s 
unusual receptor binding ability when administered to other species.  The beta subunit appears to 
confer each hormones specific biologic activity.  
Synthesis and release of LH is a regulated process and is controlled mainly by GnRH.  
Estradiol and testosterone influence secretion.  LH beta gene expression, leading to biosynthesis, 
is highly dependent on the dose of GnRH administered.  The frequency of GnRH pulses has a 
major effect on gonadotropin gene expression.  Rapid frequency elicits maximal stimulation of 
alpha and LH beta mRNA; lower frequencies signal expression of the FSH beta mRNA.  This 
unique biosynthetic mechanism allows the production of two hormones, preferentially, within 
one cell type by one signaling hormone.  In addition, the same signaling hormone stimulating 
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synthesis also signals differential release.  The magnitude of FSH release from GnRH 
stimulation is less than LH (Ursula et al, 1997). 
Equine gonadotropins have significant sialic acid content, which is unique in comparison 
to other species.  The terminal sugar on the majority of the carbohydrate side chains of both LH 
and FSH is sialic acid.    With its strongly negative charge, sialic acid imparts particular receptor 
binding abilities to the individual hormones and influences both biologic activity and circulatory 
half-life.  Sialic acid appears to decrease the degradation of LH in the mare hence increasing its 
half-life and conferring increased biologic potency. (Irvine, 1979)  Mares are unique among 
other domestic farm animals in that the LH surge leading to ovulation is prolonged beginning 
several days prior to ovulation.  This longer half-life of LH associated with the sialic acid content 
helps to explain the persistence of high concentrations of LH up to three days post-ovulation. 
(Geschwind et al, 1975) 
  
Prostaglandin F2α (PGF2α): 
Prostaglandins consist of a chain of 20-carbon fatty acids which are derived from 
arachidonic acid and control the length of the mare’s estrus cycle by determining the functional 
lifespan of the corpus luteum. (Niswender et al, 2000)  Prostaglandin F2α (PGF2α) is a very 
potent hormone with mares being 18 times more responsive to it effects than other farm species. 
(Ginther, 1992) The endometrium of the uterus produces and secretes PGF2α which, in the mare, 
reaches the ovary via the systemic circulation.  Other species have a more direct path by which 
PGF2 α reaches the ovary i.e. the counter current mechanism of the ruminant.  The path through 
the systemic circulation subjects the hormone to more rapid metabolism in the lungs, liver, and 
kidneys.  The luteal cell membranes of mares though have a much greater affinity for 
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prostaglandin in comparison to cows.  Mares actually require a much smaller exogenous dose of 
prostaglandin for clinical induction of luteolysis than cows. (Ginther, 2012) 
Prostaglandin is typically present in the blood of non-pregnant mares beginning on day 
13 post-ovulation.   The pulses of PGF2  precede the first measurable decline of systemic 
progesterone by about 3-4 hours.  Progesterone takes only 24-48 hours to decline to baseline 
(<1ng/ml). (Ginther, 2012)  On occasion, non-pregnant mares will retain function of their CL 
past this 14-17 day period of normal function.  Such mares may have depressed or absent 
pulsatile release of PGF2  from the endometrium or they may have an insensitivity to oxytocin 
stimulation causing the diestral phase of the cycle to continue beyond a normal period.  This 
persistent luteal tissue is responsive to exogenous prostaglandins. (Kindahl et al, 2000) 
Two exogenous prostaglandin products are available for use in the mare to induce 
luteolysis.  Dinoprost tromethamine (Lutalyse™, Pfizer Animal Health, New York City, New 
York, USA) and cloprostenol sodium (Estrumate™, Merck Animal Health, Summit, New Jersey, 
USA)  Dinoprost tromethamine (5mg/ml) is a natural prostaglandin approved for use in the mare 
in the USA.  A dosage of 10mg IM/1000 pounds of body weight administered at 5 days or 
greater post-ovulation ( Blanchard et al, 2003) is recommended although smaller doses have 
been found effective at inducing luteolysis.  (Nie et al, 2004)  Cloprostenol (250µg/ml) is a more 
potent analogue of prostaglandin approved for use in cattle but commonly used off label for 
estrus induction in the mare.  A dosage of 250µg IM/1000 pounds body weight is recommended 
but smaller doses have also been found effective in the mare. (Nie et al, 2004)  Both products 
appear equally effective.  Cloprostenol costs more but induces fewer side effects in mares and is 
hence a better choice for sensitive mares.  The equine CL does not become responsive to the 
effect of exogenous prostaglandin until around day 5 post-ovulation.  After terminating the 
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production of progesterone by the CL, a follicle wave must ensue for the mare to return to estrus.  
This return to estrus usually occurs in 3-7 days with ovulation occurring in from 6-10 days post 
administration. 
 
2.8 Ovulation Induction in Mares 
The purpose of ovulation induction is to better synchronize ovulation in the mare with 
mating by the stallion or insemination of semen.  It is advantageous to have ovulations occurring 
at a predictable time and increased pregnancy rates are found when semen is deposited within the 
fertile mares tract as close to ovulation as possible.(Newcombe and Cuervo-Arango, 2011) 
When using ovulation induction agents, considerations are given to sperm longevity 
within the mare’s reproductive tract. Sperm survival within the mare’s reproductive tract 
averages 2.6 days using fresh semen (Clement et al, 2000) for healthy stallions and mares, 
however, this may vary based on the individual stallion and mare. 
   Pregnancy rates for fresh semen insemination, by either artificial insemination or natural 
breeding are best from 0 to 48 hours of ovulation. For cooled, shipped semen in which sperm 
longevity is reduced from cooling, storing, and rewarming, the optimal time is 12-24 hours prior 
to ovulation up to six hours post-ovulation.   For frozen semen, which has further reduced 
longevity and viability, the best pregnancy rates occur with deposition as close to ovulation as 
possible but ideally less than 12 hours prior to ovulation and no more than 6 hours post-
ovulation. (Woods et al, 1990, Sieme et al, 2003)    
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2.9 Ovulation Induction Agents Used In the Mare 
Currently the commercially available and useful agents for ovulation induction in the 
mare are hCG (human chorionic gonadotropin) (Chorulon®, Intervet-Schering Plough Animal 
Health, USA), deslorelin (a gonadotropin releasing hormone agonist, Ovuplant™, Fort Dodge 
Animal Health, 1998) and SucroMate™, (Bioniche Life Sciences Inc., 2010 ), and r-LH 
(recombinant luteinizing hormone, EquiPure LH™, Aspenbio Pharma Inc., 2005).  Recent 
studies have also shown that the GnRH agonist histrelin (historelin) is a useful ovulation 
induction agent in the mare but no FDA approved product is yet available. (Lindholm et al, 2011; 
Voge et al, 2012) 
 Human chorionic gonadotropin (hCG) was the first drug used to induce ovulation in the 
mare in 1939.  It is a large protein hormone and bears LH like activity when used in the mare.  
Dosages used range from 1500 IU to 10,000 IU intravenously (IV), subcutaneously (SC), or 
intramuscular (IM) with the typical administered effective dose of 2000-2500 units IV or IM. 
(Berezowski et al, 2004; Barbacini et al, 2000)  The study by Barbacini and colleagues in 2000 
looked at 1040 estrous cycles during which hCG was used to induce ovulation in mares bred 
with frozen semen.    The results showed approximately 75% of mares ovulated within the 
expected time frame of 25-48 hours after injection using a dose of 2000 IU when the follicle 
measured greater than or equal to 35 mm in diameter and uterine edema was present.    Older 
mares in this study definitely showed a reduced ability to respond to the hCG and this could be 
due to antibody formation after repeated injections (Roser, 1979) or a down regulation of the 
hypothalamus, pituitary gland, and/or ovaries of older mares. (Barbacini, 2000; Clark et al, 2005)  
Hypersensitivity reactions occasionally occur after administration of hCG to mares due to its 
large size and human origin.  Another concern with Chorulon™ is its stability after 
21 
 
reconstitution. (Meyers et al, 1997)  After reconstitution with ten milliliters of sterile water 
(10,000 units total in10ml), a vial typically contains 3-4 doses depending on the amount used per 
mare.  Manufacturer recommendations are to store cooled between +2ºC to +8ºC for no more 
than 24 hours and then discard.   (Chorulon™ Data Sheet, MSD Animal Health-United 
Kingdom, Merck Animal Health, Summit, New Jersey, USA)  No clinical trials have been 
published reporting stability beyond 24 hours.  
Native GnRH products are ineffective in the mare to induce ovulation. Early work using 
gonadorelin, the native form of GnRH commonly used for induction of ovulation in cattle, 
proved unsuccessful in inducing consistent and useful ovulation in the mare even over a multiple 
dosing period. (Squires, 1981)  This short acting GnRH failed to provide the necessary prolonged 
period of LH influence on the dominant follicle required to induce ovulation in the mare even 
with the use of multiple doses.  This knowledge led to the investigation and development of 
GnRH analogues called “super agonists” for ovulation induction in the mare. (Squires et al. 
1994; Meyers et al. 1997; McKinnon et al. 1993; Ganhiem et al. 1995)  Potent synthetic GnRH 
agonists created by altering the ten amino acid composition of native GnRH proved to provide 
the necessary stimulation required for ovulation induction in the mare.  The potency of an 
agonist relates to its receptor affinity, in vivo absorption, distribution, and resistance to 
degradation and elimination. Deslorelin , buserelin, and histrelin have all proven efficacious in 
inducing ovulation in the mare (Lindholm et al, 2011; Voge et al, 2012; Barrier-Battut et al, 
2000)  Histrelin is the most potent of these three being about 210 times more potent than native 
GnRH while busrelin is only 20 times more potent.    Deslorelin is 114 times more potent.  
(Conn, 1994; Padul, 2005)  Deslorelin and histrelin are termed super agonists because of their 
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potency and prolonged effect on the hypothalamus and pituitary gland.  Presently, the most 
commonly used GnRH agonist for mares is deslorelin acetate.   
Deslorelin acetate has been released in many successful formulations: slow release 
implant (Ovuplant™ Peptech/ Fort Dodge Animal Health, 1998), short term biodegradable liquid 
(Biorelease Deslorelin, BET Pharm, Lexington, KY), aqueous, lyophilized liquid (Ferris et al, 
2011), and a recently released control released liquid (SucroMate™, Bioniche Life Sciences Inc., 
2010). All formulations have proven similar and successful at inducing ovulation in field and 
controlled studies. (Ferris et al, 2011, Ferris, et al, 2012: Berezowski et al, 2004; Jochle et al, 
2004)  Many of these formulations derive from compounding pharmacies.  SucroMate™ is 
currently the only FDA approved GnRH agonist available for use in the USA.   
Deslorelin in the slow release implant formulation (Ovuplant™) was first studied as a 
viable option for a commercially available ovulation induction agent in the mare from 1990-
1994. (Jochle et al, 1994)  This implant formulation which is injected subcutaneously in the 
tissues of the neck or vulva (McCue et al, 2002) fulfilled the need for a more consistently 
effective agent, which would shorten the interval between breeding and ovulation to 48 hours or 
less, hence increasing reproductive efficiency and without unwanted side effects.  Jochle found 
that the drug consistently accelerated the ovulation of a follicle of 30mm or greater in diameter 
and that 80% or greater of the mares in the study ovulated within 48 hours after treatment, 
reducing the time to ovulation by 5%.  No adverse effects on pregnancy rates, early embryonic 
loss, abortion rates or foal viability were noted.  No tolerance to the drug was found in individual 
mares and Ovuplant™ was found to reliably trigger LH and FSH release from the pituitary, 
lasting at least 24 hours.  Factors found to adversely influence response to treatment were 
follicles treated too early and not ready for ovulation or follicles treated too late and already 
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committed to ovulation.  Jochle did note that increasing the Ovuplant™ dose to five or ten times 
the recommended dose caused the occurrence of endocrine and clinical symptoms indicative of 
receptor down regulation at the level of the pituitary. With a five times greater dose, mares had 
an increase in the duration of estrus, an increase in the time for follicles to reach the 30 mm size 
(dominance), and an increase in the inter-ovulatory interval.  These signs were accompanied by 
increasing LH but decreasing FSH blood concentrations.  Follicles in these mares were smaller at 
ovulation but fertility was not affected.  At ten times the dose, follicular development and growth 
at the ovarian level disappeared within 15 days after treatment.  Meyers and his group also 
confirmed the findings of Jochle in two separated controlled clinical trials using a 2.2 mg implant 
vs. the 2.1 mg used by Jochle.  (Meyers et al, 1997)  Both implants were formulated by Peptide 
Technology Ltd.  
The FDA removed the Ovuplant™ product from the market due to manufacturing 
concerns in 2004.  Ovuplant™ is still approved for use in mares in the USA but, currently, must 
be imported from other countries.    In the 1998 breeding season, breeders and veterinarians 
found it quite effective in inducing ovulation in mares possessing a dominant follicle greater than 
30-35mm in size with prominent uterine edema.  Ovulation occurred consistently in 
approximately 42 hours and no decrease in efficacy occurred even after multiple doses to a 
single mare because of lack of conception and rebreeding (McKinnon, et al, 1993; Ganheim, et 
al. 1995; Samper, et al. 2002).  This made Ovuplant™ quite attractive to equine reproductive 
veterinarians and breeders.  Although the expense of the deslorelin implant was significantly 
greater than the hCG product Chorulon™, the benefit of time and dollars saved from avoiding 
the need for multiple vet exams, multiple breedings in mares susceptible to post mating 
endometritis, and multiple expensive semen shipments was a welcome trade-off.  (Meyers, et al, 
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1997)  Owners of mares enrolled as embryo donor mares were especially receptive to its use.  
Embryo donor mares are routinely given a prostaglandin injection seven days after breeding, 
immediately after the embryo flush, to return them to estrus for rebreeding and possibly 
subsequent embryo flushes.  Such mares must respond to an ovulation induction agent repeatedly 
in a shorter period of time than typical to make the endeavor successful and profitable for the 
owner. 
Recombinant equine luteinizing hormone (reLH or r-LH) is a single chain gonadotropin 
while hCG is a two chain gonadotropin (has an alpha and beta subunit).  Hence, recombinant 
equine LH is of lower molecular weight and hence less antigenic than hCG. When studied for 
use as an ovulation induction agent in 2007 by Yoon, et al, it was found to induce ovulation 
about 80-90% of the time depending on the dosage given.  The results were similar to the hCG 
treated mares (85.7%).  The study concluded that reLH was a reliable and effective ovulatory 
induction agent that did not alter endogenous hormone profiles or affect interovulatory intervals. 
(Yoon et al, 2007)   Currently it is not in active use to induce ovulation in the mare due to limited 
availability in the marketplace. 
 
2.10 The Induction of a Prolonged Interovulatory Period by Ovuplant™   
During the second breeding season in 1999, anecdotal reports of mares slow to return to 
estrus after Ovuplant™ administration started to appear. (Vanderwall et al, 2001; Morehead et al. 
2000)  Confounding these reports were the realization that mares given prostaglandin F2α after 
induction of ovulation by the deslorelin implant appeared to have an even more significant delay 
to the next ovulation. (McCue et al, 2002)  To study these questions, research ensued looking at 
the effect of deslorelin, and specifically Ovuplant™, on the hypothalamic-pituitary axis to 
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determine if the cause could be related to desensitization of the hypothalamus or down-
regulation of the pituitary.  Mares, though, appear rather insensitive to continuous GnRH 
signaling.  (Porter et al, 1997; Porter and Sharp, 2002)   
Other possible causes of a prolonged inter-estrous interval in a mare involve the gonad 
itself:  retention of function of the corpus luteum (CL) on the ovary formed at the prior estrus,  
the development of sequential secondary CLs after a primary CL is established, severe damage 
to the endometrium causing an inability to produce and release prostaglandin F2alpha (PGF2α) 
hence inhibiting lysis of the CL, the loss of an embryo past the time of maternal recognition of 
pregnancy hence prolonging the function of the CL formed at the prior estrus, or a late diestral 
ovulation leading to prolonged progesterone influence.  (Ginther, 1990)  The unique anatomy of 
the ovary of the mare has also led to difficulty in developing superovulation protocols and 
attaining good embryo recovery rates in mares having multiple ovulations on a single ovary. 
(Logan et al, 2007; Carmo et al, 2006; Riera et al, 2006)  
 
2.11 The Equine GnRH Receptor: 
The interaction of GnRH with its receptor is pivotal in the control of reproduction in all 
species.  In veterinary medicine as well as in human medicine, GnRH is studied more and more 
for use in pro- and anti-fertility roles.  Numerous agonists and antagonists have now been 
discovered to assist in these roles.  With the development of these analogues, we now understand 
that the GnRH receptor is not a unique structure unto itself. (Schneider et al, 2006) 
 In 2002, the equine GnRH receptor was cloned and sequenced by M.B. Porter and 
colleagues.  The cloned equine GnRH receptor consisted of a protein of 328 amino acids and 
showed high homology (>85%) with other mammalian GnRH receptor sequences.  This protein 
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based receptor displayed the typical conservation of key amino acids believed important for 
membrane receptor binding, trans-membrane existence, G-protein association, and 
phosphorylation.  As with most other mammalian receptors, it lacked the intracellular carboxy 
(C)-terminal tail.  The equine receptor proved unique in its amino acid sequencing:  Ser
17
and 
Ala
26
 both reside within the N-terminus, His
61
 and Asn
69
 reside in the first intracellular loop, and 
Phe
226
 resides in the fifth trans-membrane domain.  (Porter et al, 2002) 
 
2.12 The Equine GnRH Receptor Function: 
The GnRH receptor functions as a G- protein-coupled receptor (GPCR).  It is found 
primarily on the plasma membrane of pituitary gonadotroph cells. (Clayton R, 1989)  GnRH 
released from the hypothalamus associates with G-proteins of the receptor and activates a 
phosphatidylinositol-calcium second messenger system allowing for release of FSH and LH 
from the pituitary.  There are two types of GnRH and two types of GnRH receptors (GnRH-R 
Types 1 and 2).  Type 1 GnRH-R is found in most mammalian vertebrate species whereas the 
Type 2 GnRH-R has not been identified in all mammals.  Type 1 receptors have great affinity for 
GnRH I and are unique from other GPCRs in that they do not possess C-terminal tails.  This is 
the most striking difference between the two types of receptors although there are other structural 
differences.  
  Continuous stimulation of GnRH receptors leads to refractoriness, which can 
result from down regulation of the receptor or desensitization of the receptor.  Down regulation 
occurs when receptors for a hormone are internalized into the cell and then degraded hence 
disallowing a response.  Desensitization is defined as a diminishing of a response, in this case the 
release of gonadotrophs from the pituitary, in the face of sustained or repetitive GCPR 
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stimulation.  In the horse, gonadotropin secretion is much less easily suppressed by continuous 
GnRH signaling.  (Porter et al, 1997; Porter and Sharp, 2002)  Sustained stimulation of G-protein 
coupled receptors typically results in desensitization that is mediated by phosphorylation, 
commonly within this C terminal tail. (McArdle et al, 2002; McArdle et al, 1999)    Since the 
Type 1 receptor (as in the horse) lack a C-terminal tail, they are unique in that do not undergo 
agonist induced phosphorylation and desensitization.  Desensitization occurs by some other 
unique mechanism in these receptors, mostly likely distal to the receptor, but other possibilities 
are depletion of releasable gonadotropin pools, down-regulation of GnRH-R itself and inhibition 
of gonadotrophin synthesis. (McArdle et al., 2002; McArdle et al, 1999) 
Although the GnRH-R is relatively resistant to desensitization due to its structure, 
sustained exposure to GnRH can cause desensitization of GnRH-stimulated gonadotropin 
secretion.  This is an important consideration when using GnRH analogues clinically.  The exact 
mechanism of this phenomenon is not known although it is known that, upon agonist stimulation, 
the GnRH-R undergoes internalization and recycling much like other GPCRs albeit by an 
apparently different mechanism and at a reduced rate. A contributing factor in the mechanism 
may lie in yet another atypical characteristic of this receptor.  It appears to possess the ability to 
efficiently provoke a novel form of post-receptor desensitization that inhibits a signaling 
component within the pituitary cell membrane itself to inhibit functional release of 
gonadotrophin. (McArdle et al, 2002)  This effect appears slow and modest hence may not easily 
explain long term desensitization.   
Much of the study of GnRH agonist and antagonist activity has occurred in human 
medicine, the results finding application primarily in the areas of assisted reproduction and 
treatment of gonadal-related hormone disorders.  A dose- and time- dependent down-regulation 
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of promoter activity occurs in the human GnRH-R after stimulation with an agonist compound 
indicating that activation of a signaling pathway (specifically the PKC pathway) by GnRH is 
important in controlling human GnRH-R gene expression and, more specifically, plays a role in 
receptor down-regulation. (Cheng et al, 2000)  The number of receptors in the anterior pituitary 
correlates with the various stages of the reproductive cycle in rats (Clayton et al, 1980) and 
appear regulated primarily by estradiol and GnRH (a self-priming effect) .  In the rat, GnRH 
receptors are minimal on the day of estrus, double in number on diestrus day two, and remain 
elevated on the day of proestrus, leading to the conclusion that estrogen may stimulate this 
increase in receptors for GnRH.  Similar increases in receptor numbers occur in estrogen primed 
animals.  (Clayton et al, 1980; Duval et al, 2000)  
 
2.13 Current Knowledge In Breeding Mares  
Reportedly the horse was the first domestic species to undergo successful artificial 
insemination but the benefits of artificial insemination and other assisted reproductive 
technologies seem to have lagged significantly in the species. (Allen, 2005; Pickett and Voss, 
1999)  Much of the lack of early progress related to breed registry constrictions.  Over the last 
10-15 years, techniques such as artificial insemination with shipped chilled semen and frozen 
thawed semen and embryo transfer have gained approval from breed registries worldwide and 
exploration into ways improve the techniques have literally exploded.  The procedures have 
become economically feasible for horse breeders wanting to produce top progeny from their elite 
mares and stallions.   
Success of artificial insemination requires the precise timing of insemination in relation 
to ovulation.  Hence, ovulation is often pharmacologically induced to achieve this synchrony.  
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For optimal pregnancy rates, semen deposition must occur 12 hours prior to six hours after 
ovulation. (Woods et al, 1990; Sieme et al, 2003)  Embryo transfer requires this same timing not 
only to achieve pregnancy in the donor mare but also to ensure synchrony of the donor and 
recipient mare. (Allen, 2005; Allen and Rowson, 1975)  The first ovulation induction agent used 
was human chorionic gonadotropin (hCG) in 1939.  A GnRH agonist, deslorelin, came into 
popular use in the late 1990’s due to its more consistent effect of inducing ovulation.  
Both ovulation induction agents have their shortcomings but both also have their 
advantages.   hCG can often fail to induce ovulation in some mares and can invoke a 
hypersensitivity reaction but it is inexpensive.  Use of deslorelin, especially in the form of a slow 
release implant, can produce a slow return of many mares to estrus (Vanderwall et al, 2001) and 
has a much higher price tag in comparison to hCG.  Its ability to induce ovulation though proves 
much more consistent than hCG.  (McKinnon et al, 1993; Ganheim et al, 1995; Samper et al, 
2002)   
One purpose of this project was to analyze the effect of inducing ovulation in a field 
setting on reproduction efficiency and determine the value of the procedure.  The project looked 
at a large number of cycles induced to ovulate with either deslorelin (Ovuplant™) or hCG 
(Chorulon™) comparing them to estrus cycles where ovulation was not induced.  The purpose 
was not to prove one product more effective than the other but rather determine the performance 
of each product in a clinical setting in hopes of producing useful information for field 
veterinarians and breeding managers when choosing between the two agents or no ovulation 
induction.  No studies found in the literature were designed to convey this information although 
several studies completed retrospectively have examined different measures of management 
which can affect reproductive efficiency.  (Morris and Allen, 2002; Allen and Brown, 2007; 
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Bosh et al, 2009; Nath et al, 2010)   Bosh specifically looked at farm management factors which 
could influence reproductive performance but did not look at the use of ovulation induction in 
breeding management.  Nath, et al, mentions that the use of ovulation induction “was 
encouraged” by the managing veterinarian of the farms but he did specifically gather data on 
their effect.   
Deslorelin does affect the interovulatory interval of some treated mares and this has been 
well described.  (Morehead et al, 2000; Vanderwall et al, 2001;Johnson et al, 2000a and b; 
Johnson et al, 2002; McCue et al, 2002)  Although the effect is most likely related to a down-
regulation of pituitary gonadotropin secretion leading to suppression of ovarian follicular 
development (Johnson et al, 2000a) and of FSH and LH (Johnson et al, 2000b), the exact 
mechanism has not come to full clarification in the literature.  The mare is unique in her ovarian 
conformation and ovulation mechanism and research has not fully explored the option of a 
gonadal effect, specifically the function of the corpus luteum formed after the induction of 
ovulation by deslorelin (Ovuplant™).    
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CHAPTER 3  
MATERIALS AND METHODS 
 
3. 1 Study 1:  The effect of the ovulation induction agents hCG and deslorelin sustained release 
implants (Ovuplant™) on reproductive efficiency in mares  
 
Objective:  To analyze reproductive data collected from two central Illinois horse farms 
to determine if the use of ovulation induction agents improves reproductive efficiency in an 
uncontrolled, clinical setting. 
Data were collected over three consecutive years, 1999-2001. A total of 1422 cycles were 
examined from 658 mares (some mares bred in consecutive years).  Five cycles from Farm 2 
were discarded from the analysis comparing hCG with deslorelin due to the confounding 
treatment of both hCG and deslorelin in the same cycle.   
Farm 1 was located within 100 miles of Farm 2.  Both were similar in management 
styles.  Farm 1 bred a majority of Standardbred mares; Farm 2 bred a majority of American 
Quarter Horse type mares. Both farms had other breeds represented within the data set as a 
consequence of providing management of chilled semen inseminations but were of insignificant 
numbers.  Mares on both farms had rectal palpation with ultrasound performed at least every 
other day and the majority of time palpations were performed on an every other day schedule as 
is typical for most large horse breeding farms.  Inseminations for mares occurred as needed at 
least every other day.  Mares bred with chilled semen had palpations and inseminations 
performed daily or as needed.  A 37 cycles from embryo donor mares were included in the data.  
These mares would have been palpated daily after breeding to ensure the day of ovulation was 
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determined.  The ovulation induction agents used at each farm were either  hCG (Chorulon™, 
Intervet-Schering Plough Animal Health, USA) or deslorelin in the form of a short term release 
implant (Ovuplant™, Peptech Virbac Group, New South Wales, Australia).  
Data collected from records on each farm  included:  stallion used for breeding, month 
and year in which the estrus cycle occurred, the number of the cycle in years one, two or three, 
the number of palpations per cycle, the number of artificial inseminations per cycle, treatment 
given (hCG, deslorelin, no treatment), follicle size in millimeters  at treatment, days to ovulation 
after treatment, days to ovulation from the first day of estrus, the incidence of pregnancy, and the 
farm identification (Farm 1 or Farm 2).  The first day of estrus was defined as the first day a 
follicle of at least 25mm in diameter was diagnosed via trans-rectal palpation or ultrasound along 
with obvious uterine edema and a softening cervix. (Samper, et al, 1997) 
To determine the effect that ovulation induction agents have on reproductive efficiency 
and management schemes, the following hypotheses were retested:  
1.)  There is a significant difference in mare pregnancy rates associated with the use of 
ovulation induction agents.  
2.) Mares treated with an ovulation induction agent have a significant reduction in the 
number of artificial inseminations administered per cycle.  
3.) Mares treated with an ovulation induction agent have a significant reduction in the 
number of rectal palpations administered per cycle.  
4.)   Mares treated with an ovulation induction agent have are significantly more likely to 
ovulate within 48 hours of eligibility for treatment compared to mares that are not treated 
with an ovulation induction agent.  
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5.)  There is a statistically significant association between follicle size at ovulation 
induction and the number of days from treatment to ovulation when ovulation is induced 
on the first breeding examination. 
6.)  There is a statistically significant association between follicle size at ovulation 
induction and the number of days from treatment to ovulation.  
 
To determine differences between follicle sizes, recorded follicle sizes were stratified into 
4 groups: <35 mm, 35-39 mm, 40-44 mm and >45 mm.  The first breeding exam day was 
determined to be when a dominant follicle over 25 mm was first noted on at least one ovary with 
a uterine edema score of 1 or greater (score of 0-3 with 0 = no obvious edema and 3=prominent 
edema) and/or a cervical score of 1 or greater (score of 0-3 with 0 = tightly closed and 3 = fully 
relaxed).   For each follicle size, the number of AIs and palpations were recorded for each of the 
three treatment groups.  Days to ovulation was examined for each individual agent to determine 
the value of each agent at different follicle sizes and when administered on the day of the first 
breeding exam.  Each agent’s influence on the overall length of the cycle at varying follicle sizes 
was used to ascertain the most effective time to induce ovulation.   
 The data were analyzed using the IBM SPSS Statistics 20 software package.  Chi Square 
and multivariable logistic regression using a forward stepping model building approach were 
used to determine the association between probability of pregnancy and treatment.  The 
association between ovulation within two days of treatment eligibility and the treatment itself 
were determined using multivariable logistic regression.  One-Way ANOVA and multivariable 
regression were used to determine the mean number of artificial inseminations and palpations 
associated with treatment.  The Wilcoxon-Signed Ranks Test for pairwise comparisons was used 
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for post hoc analysis.  Kruskal-Wallis One Way Analysis of Variance using mean ranks was used 
to compare treatment with the number of palpations, number of AI, and days to ovulation at the 
follicle size stratifications of <35 mm, 35-39 mm, 40-44 mm, and >45 mm.   Post hoc analysis 
was performed between groups using Kruskal-Wallis All-Pairwise Comparisons Tests.   
 
3.2 Study 2: Effect of deslorelin sustained release implants on the interovulatory period and 
response to PGF2  administration 6 days after ovulation 
 
Objective:  To determine if deslorelin in the form of a sustained release implant called 
Ovuplant™ will increase the interovulatory period of the treated mares and to determine whether 
the change in interovulatory period is associated with the function of the corpus luteum formed 
at the Ovuplant
TM
 -induced ovulation.   
 
Ovuplant
TM
 is a sustained release implant that contains the gonadotropin releasing 
hormone (GnRH) agonist deslorelin and which is given to mares subcutaneously during estrus to 
induce ovulation.  Clinical evidence suggests that Ovuplant™ causes an increase in the 
interovulatory period of mares not conceiving on the treated cycle. (Vanderwall et al, 2001; 
Morehead et al. 2000)  To test the hypothesis that treatment with Ovuplant™ induces corpus 
luteum persistence beyond the normal lifespan of 12-14 days (Ginther and Beg, 2011), a 
convenience sample of six regularly cycling teaching mares housed in the University of Illinois 
Veterinary Teaching Hospital was used.  The group consisted of five Trakehner and one 
American Quarter Horse.  A crossover design clinical trial was utilized to optimize use of the 
mares and control variability. (Figure 1, Tables & Figures)  The study was conducted during the 
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months of April, May June, July, August, and September.  Prior to beginning the study, the 
mares were examined for reproductive normalcy by transrectal palpation with a 5.0 MHz linear 
array probe and a Medison Sonovet 600 ultrasound.  A normal cycle was defined as the presence 
of uterine edema, a follicle greater than 25 mm in diameter and subsequent ovulation.  Once 
normal cycling was determined, the mares were randomly assigned to a control cycle with no 
treatment, a cycle with the diestrus phase shortened with PGF2α, or an OvuplantTM treated cycle.  
The final cycle for all mares was a cycle with ovulation induced with Ovuplant™ followed in six 
days by an IM injection of dinoprost tromethamine (Lutalyse™). 
 Mares in estrus and assigned to a control cycle underwent daily trans- rectal palpation 
with ultrasound until ovulation occurred.  An example is found in Figure 2.  After ovulation, 
examinations were reduced to every 3 days allowing for determination of the interovulatory 
interval while decreasing the manipulation of the mares.   The mares were monitored for physical 
signs of a return to estrus.  Criteria for determining a return to estrus were: a uterine edema score 
greater than 0, a growing follicle over 25 mm, and a softening cervix. At the return of estrus, 
mares were palpated daily until a second spontaneous ovulation occurred.
  
This second ovulation 
ended the control cycle.  Counting the days between the two ovulations determined the baseline 
interovulatory interval for the mare. Blood for progesterone levels were taken every three days 
during the interovulatory period.  The progesterone sampling determined the function of the 
naturally induced CL for each mare. Five to seven days after the second ovulation, an injection 
of prostaglandin F2 alpha, dinoprost tromethamine (Lutalyse
TM
), was given IM to cause 
luteolysis and return the mare to estrus.   The beginning of the next heat cycle was determined by 
trans-rectal palpations every three days. Once the mare displayed signs of a return to estrus, she 
was assigned to an untreated estrus with the diestrus phase of the cycle shortened by the 
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administration of dinoprost tromethamine (Lutalyse™) six days after ovulation, the Ovuplant™ 
treatment group, or, if it was her final treatment cycle, to the Ovuplant™ followed by an 
injection of dinoprost tromethamine (Lutalyse™) treatment group.   
Mares assigned to the untreated cycle with diestrus shortened by the injection of the 
prostaglandin, dinoprost tromethamine (Lutalyse™) cycled through estrus in an natural manner.  
Six days after ovulation was detected, an injection of prostaglandin was administered with the 
intent to shorten the diestrus phase and return the mare to estrus earlier than a natural cycle.  
Rectal palpations with ultrasound were performed daily during estrus until ovulation was 
detected and then every three days until physical signs of a return to estrus were noted. Exams 
continued daily until ovulation was detected.  The interovulatory period determined for this cycle 
gave the baseline for comparison for the Ovuplant™/prostaglandin treatment cycle.  No 
progesterone sampling was completed for this cycle. 
Mares assigned to the Ovuplant
TM 
treatment group were examined daily until a 35 mm 
follicle was noted in conjunction with uterine edema and cervical softening.  At that time, 
Ovuplant was administered as per the manufacturer’s directions.  Daily monitoring continued 
until ovulation.  During diestrus, examinations were performed every 3 days and blood samples 
were drawn for progesterone analysis at each of these exams.  Upon noting signs of returning 
estrus, daily monitoring resumed until the day of the second ovulation of the treatment cycle was 
recorded. This determined the interovulatory period for the Ovuplant™ treatment cycle.  Six 
days after the second ovulation of the treatment period, dinoprost tromethamine was 
administered to shorten the interestrous interval preparing the mare for another treatment cycle.  
Mares were then examined every three days until they returned to estrus and were designated to 
another treatment group- either a control cycle or, if it was her final treatment cycle, the 
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Ovuplant™ followed by dinoprost tromethamine (Lutalyse™ ).  The purpose of the Ovuplant™ 
cycle was to determine the effect that Ovuplant™ alone had on the interovulatory period and 
functioning of the CL for each mare.  An example of this treatment cycle is found in Figure 3. 
 
The final cycle for all the mares was a cycle with ovulation induced with Ovuplant
TM
 
followed on the fifth day post-ovulation by an injection of dinoprost tromethamine to induce 
luteolysis.   As previously, the monitoring of mares occurred daily through estrus.  When a 
35mm diameter follicle was first noted, an Ovuplant
TM
 implant was administered to induce 
ovulation.  Once ovulation was detected, rectal exams were reduced to every three days through 
the diestral phase and blood samples were drawn for progesterone determination at each exam.  
Five days post ovulation (Day 1 equals the first day after ovulation was detected), an injection of 
dinoprost tromethamine was administered IM.  Upon detection of physical signs of estrus, daily 
examinations resumed until the second ovulation of the treatment cycle was detected. The 
interovulatory period was examined for a lengthening secondary to Ovuplant™ administration.  
Blood progesterone levels assisted in determining if the prostaglandin injection had induced 
luteolysis. The second ovulation on this treatment cycle ended the study.  An example of this 
treatment cycle is found in Figure 4. 
 Blood samples were drawn during the diestral phase on all treatment cycles for 
progesterone testing to evaluate the function of the CL.  Blood collection occurred by 
venipuncture of the jugular vein on the day of ovulation and every three days after until a return 
to estrus was detected.   Blood was drawn into a 10ml red topped clot tube.  Samples were 
allowed to clot for 30 minutes and centrifuged for 10 minutes to separate the serum.  Serum 
samples collected were frozen in a refrigerator freezer at 0ᵒF (-18ᵒC) for preservation. The 
samples were submitted together for analysis one month after the study ended.   
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Progesterone concentrations were determined by a modified double-antibody ELISA 
procedure of Kesler, et al (Kesler D, et al., 1990)   Modifications included  use of anti-rabbit IgG 
linked to 96 well polystyrene microtiter plates vs. polysterene tubes, use of  progesterone 
antiserum diluted at 1:50,000,  use of the substrate 3,3’,5,5’-tetramethylbenzidine (TMB), and  
evaluation of plates by spectrophotometry at an absorbance of 630nm.  Anti-rabbit IgG was 
linked to polystyrene microtiter plates via an enhanced linking procedure.  Progesterone in serum 
samples was extracted with ethyl ether.  Ether extracted hormone was reconstituted with 0.1% 
gelatin-phosphate buffered saline.  For assaying, addition of three components (100μl each) to 
the plates occurred in the following order:  1.) standards or extracted samples, 2.) conjugate, 3.) 
primary antibody (rabbit anti-goat).  Standard concentration of progesterone were 0 0.125, 0.75, 
1.5, 3, 6 ng/ml.  Conjugate was linked to horseradish peroxidase.   Secondary antibody was goat 
anti-progesterone.  Plates were incubated for 0.5 hour at room temperature and then the plates 
were washed with distilled water removing the unbound and free progesterone.  The substrate 
330 μl/well TMB was added to the plates and incubated for 30 minutes at room temperature.  
Evaluation of plates by spectrophotometry at an absorbance of 630nm occurred as the final step.  
High conjugate binding denoted by a dark blue coloration indicated low progesterone levels.  
Low conjugate binding denoted by a clear coloration indicated high levels of progesterone.   
Trans-rectal ultrasound was used to score uterine edema (0-3 with 0 = no obvious 
edema), determine follicle size in millimeters (mm), and cervical score (0-3 with 0 = tightly 
closed). An experienced evaluator was used to determine these values.  Progesterone levels were 
determined in ng/ml.   
The descriptive and logistic regression components of the statistical analysis were 
completed using the SAS 9.2 statistical software package and other testing was completed using 
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the IBM SPSS Statistic20 software.  Friedman’s two-way analysis of variance and Kruskal-
Wallis one-way nonparametric analysis of variance using mean ranks was used to compare 
treatment with interovulatory period, follicle size at treatment for the four treatment cycles, 
follicle size at ovulation for the four treatment cycles, and days to ovulation for the four 
treatment cycles.  Kruskal-Wallis all-pairwise comparisons test compared significant results.  
Progesterone levels were analyzed by treatment group using Kruskal-Wallis nonparametric 
analysis of variance and Kruskal-Wallis all-pairwise comparison test. 
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CHAPTER 4   
RESULTS 
 
 
4.1 Study 1:  The effect of the ovulation induction agents hCG and deslorelin sustained release 
implants (Ovuplant™) on reproductive efficiency in mares 
Comparison of reproduction management practices between study farms 
Across both study farms, estrus cycles treated with hCG numbered 383, cycles treated 
with deslorelin numbered 451, and 583 cycles were untreated.  See Table 2 for a detailed 
comparison of the study farms.  There were statistically significant differences between the two 
farms with respect to treatments used and timing of administration of the treatments.  Farm 1 
treated 255 mares (48.39%) with hCG while Farm 2 treated 128 (14.38%). (Table 2)  Farm 1 
treated 4 mares (0.76%) with deslorelin and Farm 2 treated 447 mares (50.22%).  Farm 1 left 268 
cycles (50.85%) untreated while Farm 2 left 315 (35.39%) untreated.  
The average days from the first reproductive exam to ovulation   for all cycles were 3.72 ± 
1.96 for Farm 1, 4.41 ± 2.07 for Farm 2 with an average for both farms of 4.16 ± 2.05 days.  
Farm 1 treated mares 0.58 days after the first sign of estrus while Farm 2 treated 1.35 days with 
the average day of treatment from first day of estrus being 1.07 days for both farms.  Treatment 
to ovulation (time from administration of an ovulation induction agent to confirmation of 
ovulation by a rectal ultrasound examination) for mares treated averaged 3.09 ± 1.86 days with 
Farm 1 having an interval of 3.14 ± 1.72 days and Farm 2 having an interval of 3.06 ± 1.95 days.  
Average number of artificial insemination per mare per cycle on Farm 1 was 1.69 and Farm 2 
was 1.08.  Average number of palpations on Farm 1 was 3.59 and Farm 2 was 2.69.  (Table 3) 
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The average diameter of a follicle treated with an ovulation induction agent (hCG or 
deslorelin) was 40.45 for hCG, 36.94 for deslorelin, and 40.17 for untreated.  Average day of 
administration for hCG was 1.5 +/- 1.81 and 2.10 +/- 1.73 for deslorelin.  Average number of 
inseminations for hCG 1.59 +/- 0.88, for deslorelin 1.21 +/- 1.06 and for untreated cycles 1.18 
+/- 0.48.   (Table 1)  Average number of palpations was 2.94 +/- 1.15 for hCG, 3.58 +/- 1.35 for 
Ovuplant and 3.20 +/- 1.36 for untreated cycles.  (Table 1)  Average time of treatment with an 
ovulation induction agent (hCG or deslorelin) to ovulation was 2.49 +/- 1.32 for hCG, 2.11 +/- 
0.74 for deslorelin, and 4.22 +/- 2.12 for untreated cycles.  (Table 1)   
   
There is a significant difference in mare pregnancy rates associated with the use of ovulation 
induction agents: 
The multivariable logistic regression model indicated that mares treated with either 
deslorelin (Ovuplant™) or hCG (Chorulon™) were over twice as likely to become pregnant as 
those left untreated (O.R. =2.187, 95% CI 1.700, 2.814, p<0.001).   The model found two 
variables of significance:  treatment (p<0.001) and an interaction term for Month*AI*DaysO 
(p<0.01). (Table 4)  The was no difference between the effect of the two treatments on 
pregnancy rate  
 
Mares treated with an ovulation induction agent have a significant reduction in the number of 
artificial inseminations administered per cycle:  
No significance difference was found between treatment and the number of artificial 
inseminations. (Table 5)  Deslorelin treated mares were inseminated a mean of 1.20 times per 
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cycle, mares treated with hCG were inseminated 1.59 per cycle, and control mares a mean of 
1.21 times.  The median number of AI for all agents was 1.00. 
To further assess the effect of ovulation induction on the number of AI, the effect of a 
treatment when given at a particular follicle size on the number of AIs was examined using 
Kruskal –Wallis one way nonparametric analysis of variance and Kruskal-Wallis all-pairwise 
comparison testing. An effect was found for the follicle size grouping 40-44 mm; (p=.000).  
(Histogram 1)  Deslorelin treatment alone decreased the number of AI at this follicle size (1.16 
AI) in comparison to hCG (1.61 AI) and untreated mares (1.48 AI).  Overall, less than two AI 
occurred on all mares for all treatment groups at all follicle sizes.  (Table 1)  
Administering an ovulation induction agent on the day of the first breeding exam  
significantly decreased the number of AI for treated mares vs. untreated mares at all follicle sizes 
except those 45mm or greater in diameter ( p=.0005). (Histogram 2)  Pairwise comparison 
testing determined that with follicles <35mm, untreated mares were inseminated a greater 
number of times (2.47 AI) in comparison to deslorelin treated mares (1.36 AI) and hCG treated 
mare (1.17 AI) (p=.001).  The same occurred at 35-39 mm follicles (untreated=1.83, deslorelin 
treated 1.13, and hCG treated= 1.38) (p=.000) and 40-44 mm follicles (untreated=1.62, 
deslorelin treated=1.14, and hCG treated=1.23) (p=.000).  
 
Mares treated with an ovulation induction agent have a significant reduction in the number of 
rectal palpations administered per cycle:  
Across all follicle sizes, ovulation induction did not decrease the number of rectal 
palpations in this study.  ANOVA showed significance (P=.000) but post hoc comparisons using 
Wilcoxon-Signed Ranks showed deslorelin treated mares had a significantly increased number of 
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palpations performed in comparison to untreated mares (p=.000) and hCG treated mares 
(p=.000).  The mean number of palpations for the control group was 3.2, the deslorelin treated 
group was 3.6 and the hCG treated group was 2.9.  The median number of palpations for treated 
and untreated mares was 3.00.  Data is presented in the appendix A.  However, a decrease in the 
number of palpations was found for mares treated when possessing a follicle less than 35 mm in 
diameter (p=.009) (Histogram 3);  pairwise comparison testing showed deslorelin treated mares 
(3.51 palpations) and hCG treated mares (3.19 palpations) were palpated less than untreated 
mares (3.92 palpations)  
Mares induced to ovulate on their first examination were palpated one to two times less 
than mares not treated at the follicle size groupings of <35 mm (p=.009) and 35-39 mm (p=.000)   
(Histogram 4).  The greatest effect was found for the smaller follicle grouping of <35mm 
(deslorelin 2.55 palpations vs. hCG 2.17 palpations vs. untreated 4.24 palpations) when 
compared to the 35-39mm follicle grouping (deslorelin 2.33 vs. hCG 2.39 palpations vs. 
untreated 2.82 palpations) (p=.000). 
 
Mares treated with an ovulation induction agent have are significantly more likely to ovulate 
within 48 hours of eligibility for treatment compared to mares that are not treated with an 
ovulation induction agent:  
No difference was found by multiple logistic regression (Table 6i) between the ability of 
hCG and deslorelin to induce ovulation in ≤ 48 hours (p=.073).  Neither agent had an average 
time to ovulation of less than forty-eight hours.  The mean time to ovulation recorded for hCG 
was 2.55 days and for deslorelin, 2.10 days.  (Table 6)  The median time to ovulation was 2.0 
days for both agents.  Most mares treated ovulated within 2 days of treatment (77%).  Mares 
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which ovulated within 2 days of eligibility for treatment were 13.7 times more likely to have 
been treated with hCG or deslorelin than not treated (O.R.=13.73; 95% CI:7.40, 25.85; p,0.001). 
(Table 6ii) 
 
There is a statistically significant association between follicle size at ovulation induction and the 
number of days from treatment to ovulation when ovulation induction occurs on the first 
breeding examination:  
    Human chorionic gonadotropin (hCG) decreased the days from treatment or eligibility for 
treatment to ovulation over untreated mares at follicles sized between 35-39 mm (p=.000) and 
40-44 mm (p=.000).  (Histogram 5)  Administration on the first breeding exam showed no 
significant effect of decreasing the days to ovulation over administering it after multiple exams.  
Ovulation was consistently reported in less than three days.  For follicle sizes 35-39 mm 
(p=.000): hCG on Day 0 was 2.72 days and on Day≥1 was 2.63days while untreated mares 
ovulated in 3.87 days.   For follicle sizes 40-44 mm(p=.000): hCG on Day 0 was  2.62 days to 
ovulation  and on Day≥1 was 2.34 days while untreated mares ovulated in 3.49 days.  
The ovulation response for deslorelin by day of administration for different follicle sizes 
also showed a decrease in the days from treatment or eligibility for treatment to ovulation for 
follicles between 35-39 mm (p=.000) and 40-44 mm (p=.000).  (Histogram 6)  This relationship 
existed whether administration was on the first exam (2.29 days or 2.67 days) or a subsequent 
exam (1.96 days, 1.97days).  Days from first eligibility to ovulation (first breeding date) for non-
treated mares were 3.87 days for follicles 35-40 mm (p=.000) and 3.49 days for follicles 40-44 
mm (p=.000).  A significant association was also noted for deslorelin at the smallest follicle sizes 
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(<35 mm follicles) when the drug was given subsequent to the time of the first exam (2.19 days; 
untreated mares 3.54 days) (p=.002).   
 
There is a statistically significant association between follicle size at ovulation induction and the 
number of days from treatment to ovulation. 
   Mares not induced to ovulate were compared to those induced to ovulate with either hCG 
or deslorelin.  Mares possessing a dominant follicle on at least one ovary with a uterine edema 
score of 1 or greater and a cervical score of 1 or greater were considered eligible for ovulation 
induction.  Comparison between the three groups was based on follicle size at administration of 
each drug or first eligibility to be induced to ovulate and the number of days to ovulation. 
(Histogram 7)  Overall, mean days from treatment or eligibility for treatment to ovulation were 
decreased for mares treated with either hCG or deslorelin in comparison to mares left untreated 
at all follicle sizes except the follicles >45 mm.   At the follicle size groupings of <35 mm 
(p=.001) and 40-44 mm (p=.000), hCG and deslorelin decreased the days to ovulation by 
approximately one day in comparison to no treatment.  For follicle sizes 35-39 mm (p=.000), 
deslorelin (2.02 days) decreased the days to ovulation compared to both hCG (2.68 days) and no 
treatment (3.87days). 
 
4.2 Study 2: Effect of deslorelin sustained release implants on the interovulatory period and 
response to PGF2  administration 6 days after ovulation 
 
1.  Hypothesis:  The interovulatory period of mare reproductive cycles treated with 
Ovuplant™ will be significantly different from those not treated with Ovuplant™.   
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2.  Hypothesis:  The interovulatory period of mare reproductive cycles treated with 
Ovuplant™ will be significantly different from those not treated with Ovuplant™ when 
luteolysis is induced at 6 days post ovulation. 
3. Hypothesis:  The serum progesterone levels of mares whose reproductive cycles were 
treated with Ovuplant™ will be significantly different from those not treated with 
Ovuplant™ when PGF2α is administered to induce luteolysis.  
The treatment titles, sequence of treatments for each mare, and the collected data are 
found in Table 7.  The longest interovulatory period noted was for Mare 5 at 42 days when 
treated with Ovuplant™.  The shortest period was found for Mare 2 and Mare 6 during their 
natural cycle followed by prostaglandin (8 days). Ovuplant™ treated mares prove to have an 
increased interovulatory period with a mean number of days between ovulations of 26. The mean 
days between ovulations for untreated mares (control cycle) was 21.67 days (p=.0062). (Table 8) 
  No effect was found for follicle size, follicle size at ovulation, or days to ovulation.  
Kruskal-Wallis one-way nonparametric analysis of variance comparing treatment ranks found a 
difference between the treatment groups.  The interovulatory period for treatment 4 (natural 
cycle w/PGF2α) differed from that of both treatment 1 (control cycle) and treatment 2 
(Ovuplant™ cycle) (p=.0112).  The interovulatory period for Treatment 3 (Ovuplant™ followed 
by PGF2α) did not differ from the other 3 treatment groups (p=.0112)   
  Table 9 presents the differences in length of interovulatory period for each treatment.   
The difference in days between the Ovuplant™ cycle and the control cycle is lengthened except 
for Mare 3 and Mare 8 where the interovulatory period was actually decreased in length 
compared to the expected average of 21 days.  The interovulatory periods for the Ovuplant™ 
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followed by prostaglandin treatment cycle and the control followed by prostaglandin cycle was 
also increased for all mares except Mare 3 for which there was no difference. 
Mean progesterone levels for each group are found in Table 10. Three sample values 
were missing for the Ovuplant™/PGF group and were discarded from analysis.  Mean 
progesterone levels were highest for the Ovuplant™ group (8.4ng/ml) in comparison to the 
control group (4.42ng/ml) and the Ovuplant™/PGF group (3.06 ng/ml).  Kruskal- Wallis one-
way nonparametric analysis of variance was used to compare progesterone levels by treatment 
group. The progesterone levels for the Ovuplant™ treatment group differed from the 
Ovuplant™/PGF group (p=.0223).  The intermediate progesterone levels of the control group 
were not found to differ from the Ovuplant™ and Ovuplant™/PGF group.  
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CHAPTER 5 
 DISCUSSION 
 
Changing economic times have altered the horse industry and challenged horse producers 
to breed fewer foals but foals of higher quality and value.  Many horse breeders have hence 
moved to assisted reproductive techniques and transported semen to assist in attaining their 
goals.  Control of the estrous cycle through management of ovulation has played an important 
role in the development of assisted reproductive techniques (Squires, et al, 1998), has allowed 
the success of transported semen in the horse breeding industry (Voss et al, 1975, Barbacini et al, 
2000).  It has also opened the door for successfully managing subfertile breeding animals. 
(Solomon, 1991; Blanchard et al, 2003)   An essential part of reproductive efficiency is the 
timely induction of ovulation with agents such as hCG (Sieme et al, 2003) and deslorelin in 
coordination with deposition of good quality, fertile semen.  
To achieve optimal pregnancy rates, deposition of semen must occur 12 hours prior or six 
hours after ovulation. (Woods et al, 1990; Sieme et al, 2003)   Two strategies can be employed to 
accomplish this time frame: multiple frequent palpations per rectum until ovulation appears 
imminent (or has recently occurred) or induce ovulation with a reliable induction agent near the 
time of semen deposition.   For maximal reproductive efficiency, the goal for breeding a mare is 
one insemination per estrus cycle with a pregnancy resulting.  (Sieme et al, 2003)  With 
economic constraints an important issue for many breeders, accurate timing of inseminations to 
avoid multiple inseminations, multiple veterinarian exams, multiple shipments of semen, and the 
overuse of aged or physically compromised stallions is important. (Blanchard et al, 2003)  
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The retrospective study was conducted to investigate whether ovulation induction 
improved reproductive efficiency in mares and how an ovulation induction agent might be used 
to maximize this efficiency.  This study examined data that was collected on a large number of 
estrous cycles, (n=1422), from two similar farms spanning period of three years. The most 
striking and interesting conclusion found in this study was that a mare induced to ovulate with 
either deslorelin or hCG was over twice as likely to become pregnant as a mare left untreated 
(Table 4). The individual ovulation induction agents themselves, deslorelin and hCG, did not 
show a difference in their effectiveness on pregnancy rate in comparison to each other.  This lack 
of difference between the two agents concurs with other studies comparing the two agents 
(Blanchard et al, 2002, Vanderwall et al, 2001).  One limitation of the study findings may be 
attributed to differences in the management practices at the two farms. Although the two farms 
were similar, there were several factors which differed between the farms which could have 
affected results. Farm management teams, including veterinarians providing care, were different 
and farm philosophy on managing mares may have varied.  Farm 1 and Farm 2 did treat a similar 
number of mares with ovulation induction agents hence there appears a similar management 
strategy to increase efficiency by decreasing the numbers of inseminations and palpations 
required to achieve pregnancy.  (Table 2)  However, Farm 2 treated more mares with deslorelin 
and Farm 1 treated more mares with hCG.  This most likely represents a difference in economic 
viewpoints between each farm’s veterinarians, managers, and/or the owners of the mares. 
(Squires, 2008)   
The major breeds on each farm differed but a diversity of breeds is actually represented 
in the study.  A previous comparison of the reproductive efficiency of two breeds, 
Thoroughbreds and Standardbreds, on several farms in the north east Victoria area of Australia 
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determined the disparity between reproductive parameters was more related to management 
decisions and not the breeds themselves (Nath et al, 2010).  The farms were located within 125 
miles of each other, potentially limiting the impact of environmental effects on reproduction.   
Farm 2 tended to induce ovulation later in the heat cycle, (Table 3) which may have indicated a 
management decision to improve conception rates by ensuring that breeding occurred as close to 
ovulation as possible.  This could be for several reasons:  stallion management (subfertility, high 
demand for semen, physical issue), availability of semen, timing of the ovulatory event as close 
to insemination as possible (secondary to poor sperm longevity secondary to chilling, freezing, 
or just poor quality) or management of mares with uterine pathology (acute and chronic 
endometritis).  (Crowe et al, 2008; Sieme et al, 2003)  Per record analysis, Farm 2 managed more 
chilled semen inseminations, embryo donor mares, and treated more mares post breeding than 
did Farm 1. 
Both farms minimized the number of palpations and artificial inseminations even on 
mares which were not treated.  (Table 1 and Table 3)  Farm 2 averaged slightly over one 
insemination per mare.  Both farms managed all mares in a manner in which, on average, less 
than four palpations were required per mare per cycle and the median number of rectal 
palpations was three. Farm 2 averaged less than 3 palpations per mare.  Optimal observation of a 
mare’s reproductive tract for breeding would require a minimum of two palpations-one prior to 
breeding to determine the optimal time of insemination and one to confirm ovulation and uterine 
health after breeding.  The management on both farms appeared to be of high quality and 
intensive.  Farm 2 may have managed slightly more intensively than Farm 1 as indicated by the 
higher percentage of mares induced to ovulate (Farm 2= 64.6% vs. Farm 1= 49.1%, Table 2).  
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Previous studies evaluating reproductive efficiency that noted the use of ovulation induction 
agents reported a use rate of approximately 51%.  (Morris et al, 2002) 
For this study, inducing ovulation appeared to have a strong positive effect on pregnancy 
outcome.  This is contrary to the results of other similar large retrospective studies evaluating 
reproductive efficiency, which found that ovulation induction had neither an significantly 
positive nor negative effect on pregnancy outcome (Allen et al, 2004;  Morris et al, 2002; 
Vanderwall, et al, 2001)   In these studies and other similar studies, other factors such as mare 
age (Morris et al, 2002; Allen et al, 2007; Bosh et al, 2009) and mare status (maiden, barren, 
foaling, aborted or rested) had the most significant effect on pregnancy and foaling rate (Morris 
et al, 2002).  Mare age and reproductive status were not specifically evaluated in this study.   
Stepwise regression analysis using a forward approach was used to determine this outcome and 
the model evaluated treatment, mare, month of insemination, number of AI, size of follicle at 
treatment, day of ovulation, and farm plus all possible interactions.  Only treatment (p=.000) and 
an interaction term of month, days to ovulation, and number of AI (p=.004) appeared significant 
and there was no significant effect of the individual mare (Table 4).  
Both randomized clinical trials  and retrospective studies have been utilized to examine 
the effect of deslorelin in comparison to placebo treated mares or non-treated mares on 
pregnancy outcome (Meyers et al, 1997;  Ganheim et al, 1995; Morehead et al, 1999).  No study 
has shown a positive effect.  Studies have also failed to establish an effect of hCG (Voss et al, 
1975) except for one large retrospective study out of New Zealand in 2001.  This study 
determined that administering hCG 24 hours prior to insemination tended to improve the odds of 
pregnancy at 14 days by approximately 21%. (Perkins et al, 2001)  Although the p value from 
multiple logistic regression for this association failed to show significance (p=.06), the authors 
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reasoned their finding as biologically meaningful by demonstrating a large sample size (2119 
ovulatory cycles) with an odds ratio of 1.21 which had a 95% confidence interval of 0.99 to 1.48 
which was primarily in the positive direction of an effect of hCG.  They also noted that the p 
value was only marginally greater than the accepted value of p=.05.   
A major advantage to induction of ovulation by deslorelin or hCG should be the 
reduction in the artificial inseminations per cycle and per pregnancy. (Meyers et al, 1997; 
Squires, 2008, Jochle et al, 1994) This study did not determine a decrease in artificial 
inseminations (AIs) for either the inclusive group of mares or the subset which became pregnant 
based on inducing mares to ovulate alone.  (Table 5 and Appendix B)  Overall, the mean number 
of inseminations per mare was low for all groups (Ovuplant = 1.19±0.52; hCG = 1.59±0.878; 
untreated = 1.21±1.06) (Table 5).  The median number of artificial inseminations per cycle was 
one.  This minimal insemination rate may have contributed to this result.   
Evaluation of the effectiveness of each ovulation agent at different follicle sizes to reduce 
the number of inseminations per cycle was used to determine if there was an optimal follicle size 
when induction of ovulation proved most beneficial to reducing the number of inseminations.  
(Histogram 1)  Both drugs were compared to no treatment at 4 follicle size groupings-<35mm, 
35-39 mm, 40-44 mm, and ≥45 mm.  Induction with deslorelin decreased the number of 
inseminations for follicles between 40 and 44 mm in diameter in comparison to both hCG and no 
treatment.  Deslorelin appeared more consistent in its ability to decrease the number of AIs over 
hCG for all follicle sizes except those less than 35mm in diameter.  No other follicle sizes 
demonstrated a significant effect of treatment over no treatment.   Again, the overall number of 
inseminations on both farms were minimal for both treated and untreated mares (Sieme H, et al, 
2003) and comparable to other retrospective studies on intensively managed farms (Morris et al, 
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2002).  Hence, it appears there was no follicle size at which induction of ovulation was more 
beneficial than any other for decreasing inseminations and improving semen usage but deslorelin 
did appear to perform better than hCG at reducing artificial inseminations.  Noting that 
performance of both ovulation induction agents was poor at follicles less than 35mm in diameter 
could have related to induction of ovulation before minimum qualifications had been meet (a 30-
35mm follicle with uterine edema and a softening cervix).  Hence, ovulation failed requiring 
more inseminations be performed.  (Barbacini S, et al, 2000; McKinnon et al, 1993) 
Analysis of the timing of administration of the induction agent showed that inducing 
ovulation at the first breeding exam when follicles were less than 45 mm in diameter proved 
most beneficial in decreasing the number of artificial inseminations. (Histogram 2)   HCG and 
deslorelin proved equally effective at this time point for reducing the number of inseminations 
for all follicle sizes except those greater than or equal to 45 mm.  There was no sparing effect at 
this follicle size in comparison to no treatment as expected since these follicles are destined for 
natural ovulation. (Ginther O, 1992; McKinnon A and Voss J, 1993)  The most notable outcome 
was the obvious difference between the number of inseminations performed on untreated mares 
possessing a follicle size <35 mm (2.47 AI) and treated mares.  Deslorelin treated mares were 
inseminated a mean number of 1.36 times and hCG treated mares were inseminated a mean 
number of only 1.17 times at this follicle size when given on the first breeding exam.  There was 
no apparent difference in this effect between hCG or deslorelin.  As follicles became larger, 
hence moving closer to natural ovulation, no difference between outcomes was significant.  One 
may conclude from the analysis that treating mares on the first breeding exam, even when 
follicles are quite small but meet the minimum requirements for ovulation induction, may prove 
most beneficial to decreasing the number of inseminations.   
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Decreasing the number of artificial inseminations would be advantageous in numerous 
regards especially if inseminations could be reduced to one per cycle with pregnancy resulting.  
Decreased inseminations prove labor saving for the farm personnel and aid in stallion 
management.  Financial advantages may be gained by clients using shipped chilled semen if only 
one shipment is required for pregnancy in a valuable mare.  (Sieme et al., 2003)  Mares 
susceptible to post mating endometritis could benefit from the reduced amount of semen placed 
within the uterus. (Pycock, 2006)  In addition, a financial reward may be obtained since an 
improved uterine environment in these mares may lead to less need for post mating uterine 
treatments and an increased likelihood of pregnancy after one mating. 
Reducing the number of palpations per cycle would have similar labor and financial 
advantages.  In this study we did not note a significant decrease in the overall number of 
palpations performed on the mares after inducing ovulation.  (Appendix A)    There are 
numerous factors which could affect the number of palpations required per cycle including 
season of the year, status of the mare as an embryo donor or recipient, breeding with semen fresh 
on farm or shipped, and the reproductive health of the mare.  No studies were found that looked 
at the effect of ovulation induction on the number of palpations performed. 
An effect of ovulation induction on the number of palpations was found when 
consideration was given to both the follicle size at administration and if administration occurred 
on the first breeding examination.  When either of the ovulation induction agents were 
administered to a mare possessing a small follicle, defined as <35 mm in diameter, the number of 
palpations were significantly decreased in comparison to untreated mares.  (Histogram 4)  The 
total number of palpations was also decreased by one to two palpations per cycle if a mare, ready 
for breeding on her first rectal ultrasound exam and possessing a follicle less than 40mm in 
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diameter, was induced to ovulate with either agent.  This indicates that induction agents should 
be given early in the heat cycle, as soon as a follicle appears of appropriate maturity for 
ovulation induction, rather than waiting, if a goal is to palpate the mare less than three times.  A 
significant savings in time and money could be obtained by following this practice. 
A final objective of this study was to determine the effectiveness of hCG and deslorelin 
in this clinical setting to induce ovulation within 48 hours of administration.  (Table 8)  This was 
a difficult association to make since the mares in this study were typically only palpated on an 
every other day basis and the time of drug administration was not recorded by the farm 
personnel.  No significant association was found using multivariable regression analysis but the 
median days to ovulation were determined to be two.  Examining mares more often throughout a 
day or daily would have given a more timely determination of ovulation but this is not practical 
in a field situation.  Meyers, evaluating the ability deslorelin to induce ovulation, found an 
overall time to ovulation of 54.1 hours when examining mares on a daily basis after induction.  
No record of the exact time of induction appeared recorded in this study and the mares did not 
appear to be check at the same time daily.  Overall, the study determined that 80.9% had 
ovulated within 48 hours. (Meyers et al., 1997)  Approximately 77% of the mares treated in this 
study had ovulated by a second breeding exam occurring two days later.   Approximately 80% of 
deslorelin treated mares had ovulated by a second breeding exam occurring two days later and 
approximately 74% of hCG treated mares had.  Another retrospective study determined the 
ovulation rate within two days of administration to be higher for both deslorelin implants (92%) 
and hCG (83%). (Berezowski et al., 2004).  These mares were also examined daily after 
induction. 
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The number of days to ovulation was notably decreased by ovulation induction for all 
follicles sizes except those follicles which were destined for natural ovulation (greater than 45 
mm). (Histogram 7) To compare treated and untreated mares at a similar point in their cycle, 
mares not treated (controls) were considered eligible for ovulation induction when they were 
bred for the first time and possessed a dominant follicle with uterine edema.   Mares not induced 
to ovulate consistently took over 3.5 days to ovulate except when possessing a follicle over 45 
mm in diameter.  Treated mares consistently ovulated in less than 3 days.  As expected, small 
follicles less than 35mm did not respond as quickly to ovulation induction with hCG (Samper et 
al, 2002) but the days to ovulation still appeared slightly decreased in comparison to non-treated 
mares.  Deslorelin appeared superior to hCG when used with follicles sized between 35-39 mm. 
Both agents performed similarly on follicles between 40 and 44 mm.  This again appears to 
reaffirm the fact that hCG may need more mature follicles to consistently induce ovulation in the 
most timely fashion.     
Analysis of both induction agents and their ability to shorten the time to ovulation when 
administered at different follicle sizes on the first breeding day was conducted to determine if 
there was a “best” time for an ovulation induction agent to be administered within the estrus 
cycle. Administering the agent hCG when a follicle was between 35 and 44 mm in diameter 
decreased the time to ovulation by approximately one day over non-treated mares.  (Histogram 
5)  Time of administration had no effect.  There appears some benefit to waiting to give hCG 
until a follicle has matured appropriately as has been previously suggested (Samper et al, 2002).   
Most likely, a mature follicle is required for consistent ovulation induction by hCG.   
Deslorelin appeared to perform better than hCG at smaller follicle sizes.  (Histogram 6)  
Deslorelin given to follicles less than 45 mm in diameter decreased the days to ovulation in 
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comparison to untreated mares and by almost a day and a half for follicles measuring 35-39 mm.  
This result was found whether given on the first day a mare was examined for breeding or on a 
subsequent exam.   
For the smallest follicles (< 35 mm in diameter) there was no difference between no 
treatment and ovulation induction on the first examination even with deslorelin administration. 
These small follicles most likely require more hormonal priming and a final maturation period 
before ovulation can occur (Ginther et al., 2003; Ginther, 2000; McKinnon A and Voss J, 1993).  
Very small dominant follicles cannot be compelled to ovulate in a shorter period than forty eight 
hours if they are not appropriately mature.  The benefit of a decreased time to ovulation cannot 
be expected from inducing ovulation on small dominant follicles less than 35mm in diameter. 
(Glazar et al., 2004; Farquhar et al., 2000; Meinert et al., 1993)  Placement of the sperm within 
the reproductive tract needs considered when inducing ovulation at small follicle sizes if 
synchronization of ovulation and insemination are critical and the amount of sperm is limited.  
 Data for this study was collected retrospectively.  Such studies utilize data previously 
collected for another reason and hence the data may prove incomplete or inaccurate.  Incomplete 
or inaccurate data can confound the statistical analysis leading to inaccurate conclusions. (Mantel 
and Haenszel, 1959: Hess, 2004) Confounders may bias data and hinder the ability to make 
accurate associations during analysis. Retrospective analysis of data however can serve as a 
valuable and inexpensive way of analyzing multiple outcomes from existing records containing 
desired information.  A retrospective study cannot yield solid conclusions but can give us leads 
to follow from which more controlled, prospective studies can be developed. (Mantel and 
Haenszel, 1959)  
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The goal of performing this retrospective study was to analyze the use of the ovulation 
induction agents by veterinarians and breeding managers in a routine clinical setting to see if 
they improve reproductive efficiency, performed as proven in controlled settings, and to 
optimistically demonstrate best use practices. The desired outcome was to determine the worth of 
using ovulation induction agents for breeding mares and how to capitalize on their use when 
managing a breeding. The results of this study are quite intriguing and have allowed us to make 
some interesting presumptions as to the worth of ovulation induction in mare breeding.  The 
study has also allowed us to deduce protocols to best utilize the drugs when managing a 
breeding.  Proving these protocols conclusively in randomized controlled trials may prove of 
significant value to horse breeders.  
From this study we can presume the relative worth of ovulation induction agents as high.  
Ovulation induction appeared to allow for an increased pregnancy rate, a decreased number of 
artificial inseminations per conception (especially when using deslorelin and administering the 
agent on the first breeding exam day), and a shortening of the estrus period of mares. A 
decreased in the number of palpations also appears possible when the agents are used earlier in 
the estrus period on small follicles, less than 35 mm, in diameter provided the follicles are 
mature enough to respond appropriately to induction.  An increased pregnancy rate would 
hopefully improve foaling rate hence increasing the number of foals produced and available for 
sale or performance.  Decreasing inseminations per pregnancy would decrease cost of semen and 
should decrease time and labor costs of gathering semen and inseminating.  The same should be 
seen with a decrease in the number of palpations per mare and per pregnancy.  Both agents 
appear to perform equally well for ovulation induction although deslorelin may perform the most 
consistently over all follicle sizes and throughout the estrus period.  If cost is secondary and 
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reliability a main concern, deslorelin may prove the best choice for ovulation induction.  If 
finances are considered when breeding a mare and reliability is secondary, hCG may be 
concluded as the best choice over deslorelin.   Ovulation induction does appear economically 
valuable when breeding mares.  A controlled study, specifically evaluating this hypothesis would 
be both relevant and desirable for the equine breeding industry.  
The clinical trial portion of this study was the first documented research on the effect of 
deslorelin on the equine ovary, specifically the CL formed at ovulation. It was conducted to 
evaluate the effect of the deslorelin sustained release formulation called Ovuplant™ on the  
interovulatory interval of mares administered the drug for ovulation induction and to examine 
progesterone production of the corpus luteum formed.  The study was small with only six mares 
used but a crossover type design allowed a total of 24 cycles to be examined.  Each mare was 
examined through four cycles (an untreated, natural control cycle, a control cycle with 
prostaglandin given to shorten the diestrus period, a cycle with ovulation induced with 
Ovuplant™, and a cycle with ovulation induced with Ovuplant™ and the diestrus phase 
shortened with prostaglandin).  A cross over clinical trial design was utilized so each mare would 
serve as her own control hence making comparison of interovulatory periods less subject to 
natural and individual mare variability. (Adams et al, 1988; Witherspoon et al, 1971; Ginther et 
al,1972; Stabenfelt et al, 1975)  Mares were randomly assigned to different treatment cycles with 
the exception of the last cycle which for every mare was the Ovuplant™ cycle followed by 
prostaglandin in six days post-ovulation.  Reportedly, this protocol may cause an even further 
delay of return to estrus for some mares. (McCue et al, 2002) 
A difference between the interovulatory periods of the four treatment groups was found 
(p=.0062).  Treatment with Ovuplant™ alone displayed the highest mean interovulatory period 
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of 26 days followed by the control cycle (21,67 days), the Ovuplant™ w/PGF2α cycle (17.33 
days), and the control w/PGF2α cycle (11.83 days). This result for the Ovuplant™ treatment was 
expected and agrees with current literature. (Vanderwall et al, 2001; Morehead et al. 2000)  The 
control cycle followed by PGF2α displayed the shortest interovulatory period as expected.   The 
Ovuplant™ cycle with the diestrus phase shortened by PGF2α did not show a difference in the 
length of the interovulatory period from the three other treatments.  Determining  no difference 
between the control cycle with the shortened diestrus and the Ovuplant™ cycle with a shortened 
diestrus indicates that the prostaglandin likely lyse the corpus luteum formed at the Ovuplant™ 
induced ovulation and the mare returned to estrus prematurely.  Examination of progesterone 
levels confirmed that the progesterone did indeed drop after prostaglandin administration on the 
Ovuplant™/PGF cycle. (Table 10) and the corpus luteum did respond as expected to 
prostaglandin administration. 
Examining the lengths of the interovulatory periods between the control with 
prostaglandin administration and the Ovuplant™ with prostaglandin administration (Table 10), a 
comparable shortening of the interovulatory period is not noted as expected.  The interovulatory 
period of the mares treated with Ovuplant™ and given prostaglandin appears longer than the 
mares undergoing an untreated estrus followed by prostaglandin.  Only Mare 3 showed equality 
in the length of the interovulatory period between the two treatments.  This supports the 
suspicion that there is an effect from the Ovuplant™ causing a prolongation of the return to 
estrus which is unrelated to the function of the corpus luteum.  Our study did not support the 
findings that the combination of the two drugs, Ovuplant™ and PGF2α, causes a further delay in 
return to estrus above and beyond that demonstrated by Ovuplant™ alone. (McCue et al, 2002)  
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No differences for the study were found comparing treatments to the days to ovulation, 
follicle size at treatment, uterine edema score or cervical score at treatment.  When examining 
the length of control cycles of the six mares, it is obvious that there was individual variation 
amongst the mares. (Table 7 and 8)  Only Mare 2, 3, and 6 displayed an expected, normal length 
for the estrous cycle of 21-22 days. (Hughes et al, 1997)  This could be due to several factors 
including individual mare variation in estrous cycling (Hughes et al, 1997, Stabenfeldt et al, 
1975; Ginther et al, 1972), an inflammation of the endometrium causing abnormal release of 
prostaglandin (Ginther, 1990), or an effect of environment, both light and temperature, since the 
mares were primarily housed within the teaching hospital (Adams, 1988; Ginther et al, 1974; 
Hughes et al, 1977).  Employing a crossover type study designed should have controlled for this 
variation but using more mares for comparison may have been beneficial. Similar variation is 
noted for individual mares treated with Ovuplant.  Mares 1, 4, 5 and 6 displayed prolonged 
interovulatory periods in comparison to their control cycles.  Mare 5 displayed a 25 day 
difference in her cycles while Mare 1, 4 and 6 displayed the more typically reported 3-6 day 
lengthening. (Johnson et al, 2002; Mumford et al, 1995)  There appears a pool of mares which 
are especially sensitive to the effects of deslorelin and Mare 5 may be one of these mares.  
(Johnson et al, 2003) 
Progesterone levels were examined every three days until a dominant follicle reappeared 
on the ovary to determine if corpus luteum function differed between untreated cycles, cycles 
with ovulation induced by Ovuplant™, and cycles with ovulation induced with Ovuplant™ and 
unnaturally shortened with prostaglandin. (Table 10) Progesterone levels after ovulation 
induction with Ovuplant™ and prostaglandin administration six days after ovulation dropped 
significantly in comparison to those found with ovulation induction with Ovuplant™ alone 
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(p=.0223).   This is agrees with other studies which have examined progesterone levels in 
association with deslorelin sustained implant use.  (Johnson et al, 2000b; Mumford et al, 1995)  
Progesterone values for the control group were intermediate to the Ovuplant™ treated 
group and the Ovuplant™/PGF2α groups.  It is expected that the progesterone values for the 
Ovuplant™ /PGF group would be lower than control and the Ovuplant™ group but it is 
interesting that the values tended higher in the Ovuplant™ group than the controls.  No 
significant difference was found in the mean values. (Table 10)  A previous study found that 
progesterone production by the corpus luteum formed by Ovuplant™ was lower than untreated 
mares (Johnson et al, 2000b) but others have noted a similar tendency toward a higher 
progesterone value (Farquhar et al, 2002) Johnson in a different study found significantly higher 
values when administering one implant daily to mares for three consecutive days in comparison 
to mares treated with one implant. (Johnson et al, 2003)  This alludes to the possibility that 
Ovuplant™ induces the formation of a corpus luteum which is higher functioning in its 
production of progesterone.  This theory has been proposed and explored in cattle (Ambrose et 
al, 1998) but has not been proven consistently in all cows (Santos et al, 2004).  Studies in canines 
has shown no difference in mean progesterone levels for dogs treated with one implant until the 
second half of gestation (or diestrus),  During the second half of gestation values drop in the 
canine because of the need for LH support of the corpus luteum.  (Volkman et al, 2006)  No one 
appears to have explored the theory of an increased production of progesterone by the CL 
formed by Ovuplant™. 
Two inherent problems arise when using a crossover study design and both are a concern 
with this study.  First is the issue of the effect of the order in which treatments are given.  Mares 
in this study were assigned randomly to treatments to dissuade bias in evaluation.  It has been 
63 
 
shown conclusively that deslorelin in the form of Ovuplant™ does have a down regulating effect 
on the hypothalamic-pituitary axis (Johnson et al, 2000a and b) unless promptly removed after 
ovulation (McCue et al, 2002).  The length of the down regulating effect on the production of 
FSH and LH appears different for individual mares.   Undergoing either Ovuplant™ treatment 
prior to the control cycles could have removed a mare from the study had that mare been 
especially sensitive to the down regulating effect of the implant and ceased to cycling.   
The second problem with the cross over study design which could have affected our 
outcome is the effect of “carry over” (i.e. the possibility of carryover of the down regulating 
effect of Ovuplant™ from one cycle to the next).  No carryover effect was noted in the study.  
Johnson in 2002 demonstrated that the down regulation of gonadotroph production appeared 
diminished by the first signs of a return to estrus.  (Johnson et al, 2002).  On the first heat post 
treatment, mares treated with Ovuplant™ do display a smaller follicle size than untreated mares 
(McCue et al, 2002; Johnson et al, 2002).   This could have confounded the determination of a 
return to heat. 
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CHAPTER 6 
CONCLUSIONS 
 
6.1 Study 1: The effect of the ovulation induction agents hCG and deslorelin sustained release 
implants (Ovuplant™) on reproductive efficiency in mares 
This study allowed us to conclude:   
 The use of the ovulation induction agents, hCG and deslorelin (Ovuplant™), may 
increase the pregnancy rate on well managed breeding farms. This is likely the result of 
better synchrony between semen placement in the reproductive tract and ovulation. 
 The use of the ovulation induction agents, hCG and deslorelin (Ovuplant™), may not 
decrease the number of artificial inseminations performed per mare on intensively 
managed breeding farms. Administering an induction on the first breeding exam day 
when the dominant follicle meets criteria for ovulation induction will decrease the 
number of inseminations needed per cycle except for follicles over 45mm in diameter.  
 The use of the ovulation induction agents, hCG and deslorelin (Ovuplant™), may not 
decrease the number of rectal palpations performed on intensively managed breeding 
farms.  If observation of a mare begins early in the estrus period, when follicle size is less 
than 35mm in diameter, than the number of palpations can be decreased significantly by 
using either agent. 
 Both hCG and deslorelin (Ovuplant™), appear equal in their ability to induce ovulation 
in a clinical setting. 
 Administering hCG or deslorelin (Ovuplant™) increases the likelihood of ovulation 
within 48 hours. 
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 Ovulation induction decreases the days to ovulation in comparison to non-treated mares.  
Days to ovulation appear affected by the follicle size at time of administration and the 
drug used.  
 hCG may perform best on dominant-type follicles over 35mm in diameter.  
 Deslorelin (Ovuplant™) appears to perform more consistently over various follicle sizes 
in comparison to hCG and appears to perform better on dominant follicles less than 
35mm in diameter in comparison to hCG. 
 The number of days to ovulation is consistently decrease by giving hCG or deslorelin 
(Ovuplant™) except when inducing large, dominant follicles over 45mm in diameter 
which are already destined for natural ovulation. 
 Ovulation induction improves reproductive efficiency by decreasing palpations, 
decreasing the number of artificial inseminations per cycle, and reducing the days to 
ovulation improving the synchrony of semen deposition with ovulation and hence the 
pregnancy rate. 
 Management of mares during breeding need considered when assessing reproductive 
efficiency 
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6.2 Study 2:  Effect of deslorelin on the interovulatory period and response to PGF2  
administration 6 days after ovulation 
This study allowed us to conclude:   
 The prostaglandin dinoprost tromethamine given six days after ovulation does effect the 
progesterone production of the corpus luteum formed after ovulation induction by the 
deslorelin sustained release implant, Ovuplant™ 
 Progesterone production by the corpus luteum formed by deslorelin sustained release 
implants is similar to untreated mares. 
 The interovulatory interval of mares induced to ovulate with deslorelin sustained release 
implants can be shortened by the administration of the prostaglandin dinoprost 
tromethamine. 
 Deslorelin sustained release implants do affect the interovulatory interval of certain  
mares and some mares appear more sensitive to their effect than others 
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CHAPTER 7   
FIGURES AND TABLES  
 
TABLES: 
Table 1:  Descriptive statistics for Study1 examining the effect of hCG, deslorelin, and no 
treatment on reproductive parameters. 
 
Cycles hCG (N=383) Ovuplant (N=451) No Treatment (N=583) 
Mean  Follicle Size at 
Treatment 
40.45±5.33 36.94±4.19 
40.17±4.89 (at first sign 
of estrus) 
Mean Day of Treatment 1.50±1.81 2.10±1.73 - 
Mean Days to Ovulation 
(from first sign of estrus) 
3.99±2.15 4.21±1.83 4.22±2.12 
Mean Days from 
Treatment to Ovulation 
2.49±1.32 2.11±0.74 - 
Mean Palpation/Cycle 2.94±1.15 3.58±1.35 3.20±1.36 
Mean AI/Cycle 1.59±0.88 1.21±1.06 1.18±0.48 
 
 
Table 2:  Comparison of the use of ovulation induction agents on Farm 1 and Farm 2. 
 
 FARM 1 FARM 2 
HCG 255 (48.39%) 128 (14.38%) 
Deslorelin 4 (0.76%) 447 (50.22%) 
No Treatment 268 (50.85%) 315 (35.39%) 
Total 527 890 
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Table 3:  Comparison of Farm 1 and Farm 2 for average day of treatment, days from treatment 
to ovulation, average number of AI and average number of palpations performed. 
 
 
 FARM 1 FARM 2 
Ave. Day of Treatment 
1
 0.58 days 1.35 days 
Days from Treatment to 
Ovulation 
3.14±1.72 days 3.06±1.95 days 
Average # of AI 1.69 1.08 
Average # of Palpations 3.59 2.69 
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Table 4: Simple Logistic Regression Model and Multivariable Logistic Regression Model for 
comparing the likelihood of pregnancy to treatment with ovulation induction agents hCG and 
deslorelin. 
 
i.)   Simple Logistic Regression Model 
Pregnant 
Chi 
Square P Value Odds Ratio 
95% Confidence Interval 
Lower Upper 
TxH 1.530 1.192 1.192 .902 1.574 
TxN 37.064 .000 2.187 1.700 2.814 
TxO - - - - - 
R
2
 is .03 (Cox and Snell) 
 
ii.)   Multivariable Logistic Regression Model  
 
Effect -2 Log Likelihood of Reduced Model Chi 
Square 
P Value 
Treatment 1903.731 42.408 .000 
Month*AI*DaysO 1869.750 8.427 .004 
R
2
 is 0.36 (Cox and Snell) 
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Table 5:  The effect of ovulation induction (with hCG or deslorelin) and no treatment on the 
number of AI for all mares in the study. 
 
 Control Treatment hCG Treatment Ovuplant 
N 584 384 454 
Missing 0 0 0 
Sum 708 610 543 
Lo 95% CI 1.1260 1.5005 1.1483 
Mean 1.2123 1.5885 1.1960 
Up 95% CI 1.2986 1.6766 1.2438 
SD 1.0621 0.8776 0.5180 
SE Mean 0.0440 0.0448 0.0243 
Min 0.000 0.000 0.0000 
Med 1.000 1.000 1.0000 
Max 8.000 6.000 5.000 
 
 
 
i.) One-Way ANOVA
a
 comparing the mean number of AI for all mares in the study across the 
three treatment groups (hCG, deslorelin, and no treatment) for pregnant mares only 
 
 Sum of Squares Mean Square F value P Value 
Regression 0.26 1 0.33 .857
b
 
Residual 1115.446 1420   
Total 1115.446    
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Table 6: The ability of deslorelin and hCG to induce ovulation within 48 hours.  
 
 Treatment hCG Treatment Ovuplant 
N 384 452 
Mean 2.5547 2.1018 
SD 1.3411 0.9550 
SE Mean 0.0684 0.0449 
Med 2.000 2.000 
 
 
i.)  Multivariable Logistic Regression Model comparing the probability of ovulation within 2 
days across the two treatment groups (hCG and Ovuplant), controlling for: Size at Treatment, 
Day of Treatment and Farm. 
Variables  P value 
Treatment 
Size at treatment 
Days of treatment 
Farm 
 .659 
.654 
.480 
.253 
 
ii.)  Chi square analysis for the association between treatment with hCG or deslorelin and ovulation 
within 2 days.  (OR=13.733; 95%CI: 7.396, 25.850; p<0.001) 
 
  Ovulation within 2 days Failure to Ovulate within 
2 days 
Treated 645 191 
Control 15 61 
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Table 7:  Data collected for each mare in Study 2 including treatment identification, treatment 
order, interovulatory period in days, follicle size in millimeters at treatment, days to ovulation, 
uterine edema score, and cervical score. 
 
 
  
 
 
  
Mare 
# 
Treatment Cycle 
Treat
ment 
Period 
Interovulatory 
Interval 
Follicle 
Size 
(mm) at 
Treatme
nt 
 
Days To 
Ovulatio
n 
Uterine 
Edema 
Score 
Cervical 
Score 
 1 (Control Cycle) 3 34 36 3 1 2 
1 2 (Ovuplant) 1 40 37 3 1 3 
 3 (Ovuplant/PFG) 4 19 42 2 2 1 
 4 (Control/PGF) 2 16 39 5 2 0 
 1 (Control Cycle) 3 23 37 1 1 0 
2 2 (Ovuplant) 1 15 39 6 0 0 
 3 (Ovuplant/PFG) 4 20 37 2  2 
 4 (Control/PGF) 2 8 37 2 1 2 
 1 (Control Cycle) 2 21 47 3 2 2 
3 2 (Ovuplant) 3 16 32 2 1 0 
 3 (Ovuplant/PFG) 4 12 44 2 2 1 
 4 (Control/PGF) 1 12 47 2 2 1 
 1 (Control Cycle) 1 14 48 11 1 1 
4 2 (Ovuplant) 3 19 45 3 1  
 3 (Ovuplant/PFG) 4 14 43 1 3 1 
 4 (Control/PGF) 2 13 32 1 1 0 
 1 (Control Cycle) 2 17 40 3 3 2 
5 2 (Ovuplant) 3 42 37 2 2 1 
 3 (Ovuplant/PFG) 4 17 41 2 2 1 
 4 (Control/PGF) 1 14 48 4 2.5 2 
 1 (Control Cycle) 3 21 41 3 2 1 
6 2 (Ovuplant) 2 24 46 3 2 1 
 3 (Ovuplant/PFG) 4 22 33 1 1 1 
 4 (Control/PGF) 1 8 39 2 2 1 
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Table 8: Friedman Two-Way Non-Parametric Analysis of Variance comparing the association 
between treatment and the interovulatory period of the six mares in Study 2.  
i) Mean rank and sample means for the interovulatory period of the six mares. 
 
Treatment Mean Rank of Treatment Mean Interovulatory Period (Days) 
1 (Control Cycle) 3.0 21.67 
2 (Ovuplant™ Cycle) 3.5 26.00 
3 (Ovuplant™/PGF2α) 2.42 17.33 
4 (Untreated Cycle/PGF2α) 1.08 11.83 
 
ii.) F= 12.368; p=.0062; degrees of freedom=3. 
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Table 9:  Calculation of the difference in the interovulatory periods in days between treatments 
for each mare in Study 2. 
 
Mare 
# 
Treatment Cycle 
Treat
ment 
Period 
Interovulatory 
Interval 
OV/C OV/OVPG C/PG 
CPG/OV
PG 
 1 (Control Cycle) 3 34 6 21 18 -3 
1 2 (Ovuplant) 1 40     
 3 (Ovuplant/PFG) 4 19     
 4 (Control/PGF) 2 16     
 1 (Control Cycle) 3 23 -8 -5 15 -12 
2 2 (Ovuplant) 1 15     
 3 (Ovuplant/PFG) 4 20     
 4 (Control/PGF) 2 8     
 1 (Control Cycle) 2 21 -5 4 9 0 
3 2 (Ovuplant) 3 16     
 3 (Ovuplant/PFG) 4 12     
 4 (Control/PGF) 1 12     
 1 (Control Cycle) 1 14 5 5 1 -1 
4 2 (Ovuplant) 3 19     
 3 (Ovuplant/PFG) 4 14     
 4 (Control/PGF) 2 13     
 1 (Control Cycle) 2 17 25 25 3 -3 
5 2 (Ovuplant) 3 42     
 3 (Ovuplant/PFG) 4 17     
 4 (Control/PGF) 1 14     
 1 (Control Cycle) 3 21 3 3 13 -14 
6 2 (Ovuplant) 2 24     
 3 (Ovuplant/PFG) 4 22     
 4 (Control/PGF) 1 8     
 
 
  
75 
 
Table 10:  Progesterone analysis for Study 2 using Kruskal-Wallis One-Way Nonparametric 
AOV (P=.0223) and Kruskal-Wallis All-Pairwise Comparison Testing.   
 
Variable Mean Homogenous groups 
O 17.33 A 
N 11.00 AB 
OPGF 7.5 B 
Α=0.05; Z value=2.394 
 
 
 
N=No treatment (control) 
O=Ovuplant treatment only 
OPGF=Ovuplant treatment with prostaglandin 
 
  
 Control 
(Untreated)  
Ovuplant Treated  Ovuplant treatment 
w/PGF2α 
N 9 9 6 
Missing 0 0 3 
Mean 5.42 ng/ml 8.40 ng/ml 3.06 ng/ml 
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HISTOGRAMS: 
 
Histogram 1:  The mean number of AIs performed during an estrus cycle at a particular follicle 
size comparing mares treated with hCG, mares treated with deslorelin and mares not treated. 
[Ovu= deslorelin (Ovuplant™)); hCG=human chorionic gonadotropin (Chorulon™); None= 
untreated mares] 
 
 
1
P values: <35mm=.000; 35-39mm=.004; 40-44mm=.000; >45mm=.000 
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Histogram 2: The mean number of AIs performed during an estrus cycle at a particular follicle 
size when ovulation induction was performed with either hCG or deslorelin on the first day a 
mare was examined for breeding and met the requirements for ovulation induction.  [Ovu= 
deslorelin (Ovuplant™)); hCG=human chorionic gonadotropin (Chorulon™); None= untreated 
mares] 
 
 
 
1
First day of eligibility for ovulation induction for treated mares=day of ovulation induction; 
untreated mares first day of eligibility=first breeding date.  
2
P values:  <35mm=.001; 35-39mm=.000; 40-44mm=.000 
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Histogram 3:  The mean number of palpations performed in an estrus cycle at a particular 
follicle size when ovulation induction was performed with either hCG or deslorelin in 
comparison to no treatment. [Ovu= deslorelin (Ovuplant™)); hCG=human chorionic 
gonadotropin (Chorulon™); None= untreated mares] 
 
 
 
1
P values:  <35mm=.009; 35-39mm=.000; 40-44mm=.000; >45mm=.001 
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Histogram 4:  The mean number of palpations performed during an estrus cycle at a particular 
follicle size when ovulation induction was performed with either hCG or deslorelin on the first 
day a mare was examined for breeding and met the requirements for ovulation induction.  [Ovu= 
deslorelin (Ovuplant™)); hCG=human chorionic gonadotropin (Chorulon™); None= untreated 
mares] 
 
 
 
1
First day of eligibility for ovulation induction for treated mares=day of ovulation induction; 
untreated mares first day of eligibility=first breeding date.  
2
P values:  <35mm=.003; 35-39mm=.000 
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Histogram 5:  A comparison of the days to ovulation for hCG based on time of administration 
and follicle size.  [Day 0=first day examined and meeting criteria for ovulation induction; 
Day≥1=day of estrus other than first day examined (Day 0); Control=Mares not treated with 
deslorelin or hCG] 
 
 
1 
Day of treatment=first day examined for breeding 
2 
P values:  35-39mm=.000; 40-45mm=.000; >45mm=.033 
* Control mares=first breeding day 
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Histogram 6:  A comparison of the number of days to ovulation assessing time of administration 
for deslorelin and follicle size at administration.  [Day 0=first day examined and meeting criteria 
for ovulation induction; Day≥1=day of estrus other than first day examined (Day 0); 
Control=Mares not treated with deslorelin or hCG] 
 
 
 
1
 Day of treatment=first day examined for breeding 
2
P values:  <35mm=.002; 35-39mm=.000; 40-44mm=.000. 
* Control mares=first breeding day 
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Histogram 7:  The number of days to ovulation for varying follicle sizes comparing mares not 
induced to ovulate (but meeting the minimum requirements for ovulation induction=eligibility) 
to mares induced to ovulate with hCG or deslorelin. [Ovu= deslorelin (Ovuplant™)); 
hCG=human chorionic gonadotropin (Chorulon™); None= untreated mares] 
 
 
 
1
First day of eligibility for ovulation induction for treated mares=day of ovulation induction; 
untreated mares first day of eligibility=first breeding date.  
2
P values:  P value:  <35mm=.001; 35-39mm=.000; 40-44mm=.000; >45mm=.027 
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Figures: 
Figure 1:  Crossover type design utilized to study the effect of Ovuplant™ on the interovulatory 
period of mares induced to ovulate and administered PGF2  5 days after ovulation 
 
 
 
 
  
Final Cycle 
Normal Cycling Mare 
Normal (Control) Cycle 
Palpation daily in 
estrus until OV→ every 
3rd day palpation (in 
diestrus) until next OV 
Ovuplant Cycle 
Palpation daily until 
≥35mm follicle→, 
Ovuplant given→ daily 
palpation until OV→ 
every 3rd d palpation 
until next OV 
Return to Estrus 
Assigned to new 
group; daily palpations 
resume 
Return to Estrus 
Assigned to new 
group; daily palpations 
resume 
Ovuplant w/PGF 
Palpation daily until 
≥35mm follicle→ Ovuplant 
given→ daily palpation 
until OV→ every 3rd d 
palpation until next OV 
PGF2α PGF2α 
End of Study Evaluations 
Control Cycle w/PGF2α 
Palpation daily in estrus 
until OV→ every 3rd 
day palpation (in 
diestrus) until next OV 
PGF2α 
Return to Estrus 
Assigned to new 
group; daily 
palpations resume 
Final Cycle 
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Figure 2: Timeline displaying treatment protocol and progesterone sampling for Mare 1 during 
the Control cycle of Study 1.   Control cycle was the second treatment cycle for this mare. 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=Progesterone sampling (every 3 days in diestrus) 
OV=Ovulation  
RO=Right Ovary 
LO=Left Ovary 
Edema=Endometrial edema scored from 0-3 with 0 equal to no edema present to 3 indicating maximal 
edema visible on ultrasound 
Cervix= Assessment of cervical relaxation determine by rectal palpation on a scale of 0-3 with 0 tightly 
closed and 3 fully relaxed 
PGF2α=Prostaglandin injection given to return mare to estrus 
  
LO  30mm 
E1, C1 
June 15 June 21 
LO CL 
6d Estrus 
LO 28 
E0, C0 
July 11 
LO43, RO28 
E2, C1 
 
Diestrus  22 days 
(Prolonged) 
( 
July 13 
LO CL 
PGF2α 
July 19 
June 11 PGF2α 
P1 P2 P3 P4 P5 P6 
Estrus 3d 
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Figure 3: Timeline displaying treatment protocol and progesterone sampling for Mare 1during 
the Ovuplant™ treatment cycle of Study 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=Progesterone sampling (every 3 days in diestrus) 
OV=Ovulation  
RO=Right Ovary 
LO=Left Ovary 
Edema=Endometrial edema scored from 0-3 with 0 equal to no edema present to 3 indicating maximal 
edema visible on ultrasound 
Cervix= Assessment of cervical relaxation determine by rectal palpation on a scale of 0-3 with 0 tightly 
closed and 3 fully relaxed 
PGF2α=Prostaglandin injection given to return mare to estrus 
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P P P P
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Figure 4: Timeline displaying treatment protocol and progesterone sampling for Mare 3 during 
the Ovuplant™ with PGF2α administered 6 days after ovulation treatment cycle of Study 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
P=Progesterone sampling (every 3 days in diestrus) 
OV=Ovulation  
RO=Right Ovary 
LO=Left Ovary 
Edema=Endometrial edema scored from 0-3 with 0 equal to no edema present to 3 indicating maximal 
edema visible on ultrasound 
Cervix= Assessment of cervical relaxation determine by rectal palpation on a scale of 0-3 with 0 tightly 
closed and 3 fully relaxed 
PGF2α=Prostaglandin injection given to return mare to estrus 
  
 
Ovuplant 
July 6 
July 8 
OV  
Onfi
P1 P2 
9 day diestrus 
OV 
3 day estrus 
LO 43mm, 
Edema2, Cervix 1 
P3 
July 17 
PGF2α 
LO 38mm, Edema 
1, Cervix 2  
87 
 
REFERENCES 
 
Ambrose J.D., M.F.A. Pires, et al. (1998)  “Influence of deslorelin (GnRH-agonist) implant on 
the plasma progesterone, first wave dominant follicle and pregnancy in dairy cattle”. 
Theriogenology 50: 1157-1170. 
Adams, G. and W. Bosu  (1988). “Reproductive physiology of the non-pregnant mare”. 
Veterinary Clinics of North America: Equine Practice 4(2):161-173. 
Alexander, S. and C. Irvine (1987). “Secretion rates and short-term patterns of gonadotropin-
releasing hormone, FSH and LH throughout the periovulatory period in the mare”.  Journal of 
Endocrinology 114:351-362.  
Allen, W.R. (2005). “The development and application of the modern reproductive technologies 
to horse breeding”. Reproduction in Domestic Animals 40:310-329. 
Allen, W.R., L. Brown, et al. (2007). “Reproductive efficiency of Flatrace and National Hunt 
Thoroughbred mares and stallions in England”. Equine Veterinary Journal 39(5): 438-445. 
Allen, W.R. L.E.A. Rowson. (1975) “Transfer of ova between horses and donkeys”. Proceedings 
of the 7
th
 International Congress on Animal Reproduction & Artificial Insemination: 484-487. 
Barbacini, S.,  G. Zavaglia, et al. (2000). “Retrospective study on the efficacy of hCG in an 
equine artificial insemination programme using frozen semen”.  Veterinary Education 12(6) 312-
317.  
Barrier-Battut, I., N. Le Poutre, (2001). “Use of buserelin to induce ovulation in the cyclic 
mare”.  Theriogenology 55:1679-1695. 
Berezowski, C.J., K.L. Stitch, et al. (2004). “Clinical Comparison of 3 Products Available to 
Hasten Ovulation in Cyclic Mares”. Veterinary Review 24(6): 231-233. 
Blanchard, T., D. Varner, et al. (2003). Manipulation of the estrus cycle in the mare.  Manual of 
Equine Reproduction, 2
nd
 ed. St. Loius, MO: Mosby, Inc; p. 20. 
Bosh, K.A., D. Powell, et al. (2009). “Reproductive performance measures among Thoroughbred 
mares in central Kentucky, during the 2004 mating season”.  Equine Veterinary Journal 41(9): 
883-888. 
Clark, I., and S. Pompolo (2005). “Synthesis and secretion of GnRH”. Animal Reproduction 
Science 88: 29-55. 
Clayton, R., A. Soalano, et al. (1980). “Regulation of pituitary receptors for gonadotropin-
releasing hormone during the rat estrous cycle.” Endocrinology 107(3): 699-706. 
88 
 
Clayton, R. N. (1989). “Gonadotrophin-releasing hormone: Its actions and receptors”. Journal of 
Endocrinology 120:11-19. 
 
Clement, F., P. Vincent, et al. (2000). “Which insemination results in fertilization when several 
are performed before ovulation?”. Journal of Reproduction and Fertility Supplement 56: 579-85. 
Conn, M. (1994). “Gonadotropin-releasing hormone and its analogues”. Annual Reviews in 
Medicine 45:391-405.  
Crowe, C., P. Ravenhill, et al. (2008). “A retrospective study of artificial insemination of 251 
mares using chilled and fixed time frozen-thawed semen”.  Equine Veterinary Journal 40(6): 
572-576. 
Donadeu, F., O. Ginther (2001). “Effect of number and diameter of follicles on plasma 
concentrations of inhibin and FSH in mares”.  Reproduction 121: 897-903. 
Donadeu, F., and E. Watson (2007). “Seasonal changes in ovarian activity:  Lessons learnt from 
the horse”.  Animal Reproduction Science 100: 225-242. 
Driancourt, M. (1991). “Follicular dynamics in sheep and cattle”. Theriogenology 35(1): 55-79. 
Duval, D., A. Farris, et al. (2000). “Responsiveness of the ovine gonadotropin-releasing hormone 
receptor gene to estradiol and gonadotropin-releasing hormone is not detectable in vitro but is 
revealed in transgenic mice”. Endocrinology 141(3): 1001-1010. 
Farquhar V.J., P. McCue, et al. (2000). “Efficacy of the GnRH agonist deslorelin acetate for 
inducing ovulation in mares relative to age of mare and season”. Journal of Equine Veterinary 
Science 20:8-11. 
Ferris, R.A., A. R.G. Lindholm, et al. (2011). “Efficacy of lyophilized deslorelin on induction of 
ovulation in mares”.  Clinical Theriogenology 3(2):99-103. 
Ferris, R.A., J.N. Hatzel, et al. (2012) “Efficacy of deslorelin acetate (Sucromate) on induction of 
ovulation in American Quarter Horse mares”.  Journal of Equine Veterinary Science 32:286-288. 
Ganheim. A.and W. Jochle (1995). “Acceleration and timing of fertile ovulation in cyclic mares 
with a deslorelin implant”. Acta Veterinaria Scandinavica 36(4):393-400. 
Gastal, E., D. Bergfelt, et al. (1999). “Role of luteinizing hormone in follicle deviation based on 
manipulating progesterone concentrations in mares”. Biology of Reproduction 61:1492-98. 
Gastal, E., M. Gastal, G.Nogueira, et al. (1999). “Temporal interrelationships among luteolysis, 
FSH, and LH concentrations and follicle deviation in mares”. Theriogenology 53:925-40. 
Gastal, E., M. Gastal, M. Wiltbank, et al. (1999). “Follicle deviation and intrafollicular and 
systemic estradiol concentrations in mares”. Biology of Reproduction 61:31-9. 
89 
 
Geschwind, I.I., R. Dewey, et al. (1975).  “Plasma LH levels in the mare during the estrous 
cycle”.  Journal of Reproduction and Fertility Supplement 23:207-212. 
Ginther, O.J., M. A. Beg, et al. (2003). “Mechanism of follicular deviation in monovular farm 
species.”  Animal Reproduction Science 78:239-257. 
Ginther, O.J., M. A. Beg, et al. (2011). “Hormone concentration changes temporally associated 
with the hour of transition from preluteolysis to luteolysis in mares”.  Animal Reproduction 
Science 129: 67-72. 
Ginther, O., E. Gastal, et al. (2008). “Dynamics of the equine pre-ovulatory follicle and 
periovulatory hormones: what’s new?”.  Journal of Equine Veterinary Science 28(8):454-460. 
Ginther, O.J. (1990). “Prolonged luteal activity in mares-a semantic quagmire”. Equine 
Veterinary Journal 22(3): 152-156. 
Ginther, O.J. (2012). “The end of the tour de force of the corpus luteum in mares”. 
Theriogenology 77:1042-1049. 
Ginther OJ. (1992) Reproductive Hormones: Gonadotropin- Releasing Hormone. Reproductive 
Biology of the Mare, Basic and Applied Aspects, 2
nd
 ed. Cross Plains, WI: Equiservices 
Publishiing; p.58-9, 269, 271; 51-54 
Ginther, O.J. (2000). “Selection of the dominant follicle in cattle and horses.” Animal 
Reproduction Science 60-61:61-79. 
Ginther, O., H. Whitmore, et al. (1972). “Characteristics of estrus, diestrus, and ovulation in 
mares and effects of season and nursing”. American Journal of Veterinary Research 
33(10):1935-1939. 
Ginther, O. (1974) “Occurrence of anestrus, estrus, diestrus, and ovulation over a 12 month 
period in mares”.  American Journal of Veterinary Research 35(9):1173-1179. 
Glazar, B.S., P. McCue, et al.(2004) “Deslorelin on days 8 or 12 postovulation does not luteinize 
follicles during an artificially maintained diestrous phase in the mare”. Theriogenology 62:57-64. 
Greaves, H., M. Porter, et al. (2000). “Effect of oestradiol on LH secretion and pituitary 
responsiveness to GnRH in ovariectomized mares”. Journal of Reproduction and Fertility 
Supplement 56:227-237. 
Greaves, H., V. Kalariotes. et al. (2001).  “Effects of ovarian input on GnRH and LH secretion 
immediately postovulation in pony mares”. Theriogenology 55: 1095-1106. 
 
90 
 
Hart, P., E. Squires, et al. (1984). “Seasonal variation in the hypothalamus content of 
gonadotropin-releasing hormone (GnRH), pituitary receptors for GnRH, and pituitary content of 
luteinizing hormone and follicle-stimulating hormone in mares”.  Biology of Reproduction 
30(5):1055-1062. 
Hess, D.R. (2004) “Retrospective studies and chart reviews”. Respiratory Care 49(10): 1171-
1174. 
Hughes, J., G. Stabenfeldt, et al. (1975). “The oestrus cycle of the mare”.  Journal of 
Reproduction and Fertility Supplement 23:161-166. 
Hughes, J., G. Stabenfeldt, et al. (1977). “The estrous cycle of the mare and its uterine control”. 
Australian Veterinary Journal 53:415-19. 
Hughes, J., G. Stabenfeldt, et al. (1980). “The estrous cycle and selected functional and 
pathologic abnormalities in the mare”.  Veterinary Clinics of North America: Large Animal 
Practice 2(2) 225-239. 
Irvine, C. and S. Alexander (1994). “The dynamics of gonadotropin-releasing hormone, LH and 
FSH secretion during the spontaneous ovulatory surge of the mare as revealed by intensive 
sampling of pituitary venous blood.”. Journal of Endocrinology 140(2): 283-295. 
Irvine C and Alexander S. (1993) GnRH.. Equine Reproduction, A McKinnon and J Voss. 
Malvern, PA:  Lea & Febiger; p. 37-43. 
Irvine, C. H. G. and Margaret J.Evans (1979). “Recent advances in reproductive endocrinology 
of the mare”. New Zealand Veterinary Journal 27(9):176-180. 
Janovick, J., F. Haviv, et al. (1993). “Differential orientation of a GnRH agonist and antagonist 
in the pituitary GnRH receptor”.  Endocrinology 133(2): 942-45. 
Jochle, W., and T. E. Trigg (1994). “Control of ovulation in the mare with Ovuplant™. A short-
term release implant (STI) containing the GnRH analogue deslorelin acetate: Studies from 1990 
to 1994.”.  Journal of Equine Veterinary Science 14(12): 632-644. 
Johnson, C., D. Thompson Jr., et al. (2000a). “LH and FSH response to GnRH in mares 
following treatment with Ovuplant’.  Proceedings of the Seventh Equine Nutrition and 
Physiology Symposium (Warrenton): 69-70. 
Johnson, C., D. Thompson Jr., et al. (2000b). “Prolonged interovulatory interval and hormonal 
changes in mares following the use of Ovuplant™ to hasten ovulation”.  Journal of Equine 
Veterinary Science 20(5):331-36. 
91 
 
Johnson, C., D. Thompson Jr., et al. (2002).  “Pituitary responsiveness to GnRH in mares 
following deslorelin acetate implantation to hasten ovulation”.  Journal of Animal Science 80: 
2681-2687. 
Johnson, C., D. Thompson Jr., et al. (2003). “Effects of deslorelin acetate implants in horses: 
Single implants in stallions and steroid-treated geldings amd multiple implants in mares”.  
Journal of Animal Science 81: 1300-1307. 
Kesler, D, H. Khazali, et al.. (1990). “Quantification of steroids via a polymer linked second 
antibody enzyme immunoassay system: methods of linking anti-rabbit IgG to polystyrene”.  
Progress In Biomedical Polymers. C.G. Gebelein & R.L. Dunn. Plenum Press, NY; p. 157. 
Kindahl, H., K. Odensvik,,et al. (2000) “Changes in PGF2alpha secretion during prolonged 
luteal phase in mares.” Journal of Reproduction and Fertility Suppl. 56:305-15. 
Koskinen, E., H. Lindeberg, et al. (1990). “Milk and serum progesterone levels in mares after 
ovulation”. Acta Veterinaria Scandinavica 31(4):441-444. 
Lindholm, A., D. Ferris, et al. (2011). “Comparison of deslorelin and histrelin for induction of 
ovulation in mares”.  Journal of Equine Veterinary Science 31:230-31. 
Logan, N.L., P.M. McCue, et al. (2007).  “Evaluation of three equine FSH superovulation 
portocols in mares”.  Animal Reproduction Science 102: 48-55. 
Mantel, N., and W. Haenszel (1959).  “Statistical aspects of the analysis of data from 
restrospective studies of disease”. Journal of National Cancer Institute 23(4): 719-748.  
McArdle, C., J. Davidson, et al. (1999). “The tail of the gonadotropin-releasing hormone 
receptor: desensitization at, and distal to, G protein-coupled receptors”.  Molecular and Cellular 
Endocrinology 151:129-36. 
McArdle, A., J. Franklin, et al. ( 2002). “Signaling, cycling and desensitization of gonadotropin-
releasing hormone receptors”.  Journal of Endocrinology 173:1-11. 
McCracken, J., E. Custer, et al. (1999).  “Luteolysis: a nueroendocrine-mediated event”.  
Physiology Reviews 79(2): 263-324. 
McCue, P., V. Farquhar, et al. (2002). “Removal of deslorelin (Ovuplant™) implant 48h after 
administration results in normal interovulatory intervals in mares” Theriogenology 58:865-870. 
McCue, P.M., Hudson J.J., et al. (2004) “Efficacy of hCG at inducing ovulation: a new look at 
an old issue”. Proceedings of the 50th Annual Convention of the American Association of Equine 
Practitioners, Denver, CO, USA: 510-513. 
92 
 
McKinnon, A., A. Nobelius,  et al. (1993). “Predictable ovulation in mares treated with an 
implant of the GnRH analogue deslorelin”.  Equine Veterinary Journal 25(4) 321-323. 
Meinert C., J.F.S. Silva, et al. (1993) “Advancing the time of ovulation in the mare with a short 
term implant releasing the GnRH analogue deslorelin”. Equine Veterinary Journal 25:65-68. 
Meyers, P., T. Bowman, et al. (1997).  “Use of the GnRH analogue, deslorelin acetate, in a slow-
release implant to accelerate ovulation in oestrous mares”.  The Veterinary Record 140:249-252. 
Miller, K., S. Berg, et al. (1980). “Concentration of circulating gonadotropins during various 
reproductive states in mares”.  Biology of Reproduction 22(4):744-50. 
Morehead, J., T. Blanchard, et al. (2000). “Clinical experience with deslorelin (Ovuplant ™) in a 
Kentucky thoroughbred broodmare practice (1999)”.  Journal of Equine Veterinary Science 
20(6): 358-402 
Morris, L.H.A.,and W.R. Allen (2002). “Reproductive efficiency of intensively managed 
Thoroughbred mares in Newmarket”.  Equine Veterinary Journal 34(1): 51-60. 
Mumford E.L., E.L. Squires, et al. (1995) “Use of deslorelin short-term implants to induce 
ovulation in cycling mares during three consecutive estrous cycles”. Animal Reproduction 
Science 39: 129-140. 
Nagy, P., D. Guillaume, et al. (2004). “Factors affecting plasma progesterone concentrations and 
the retrospective determination of time of ovulation in cyclic mares”. Theriogenology 61(2-
3):203-214. 
Nath, L., G. Anderson, et al.(2010).  “Reproductive efficiency of Thoroughbred and 
Standardbred horse in north-east Victoria”.  Australian Veterinary Journal 88(5):169-178. 
Newcombe, J.R. and J. Cuervo-Arango. (2010) “The effect of time of insemination with fresh 
cooled transported semen and natural matting relative to ovulation on pregnancy and ebryo loss 
rates in the mare”. Reproduction in Domestic Animals 46:678-681. 
Nie, G., A. Goodin, et al. (2004). “How to reduce drug costs and side effects when using 
prostaglandins to short-cycle mares.” American Association of Equine Practitioners Proceedings 
50:396-98. 
Niswender, G., J. Juengel, et al. (2000). “Mechanisms controlling the function and lifespan of the 
corpus luteum”.  Physiology Review 80:1-29. 
Padula, A.  (2005). “GnRH analogues-agonist and antagonists”.  Animal Reproduction Sciences 
88:115-126. 
93 
 
Perkins, N., and J. Grimmett (2001). “Pregnancy and twinning rates in Thoroughbred mares 
following the administration of human chorionic gonadotropin (hCG)”.  New Zealand Veterinary 
Journal 49(3): 94-100. 
Pickett B.W., J.L. Voss. (1999) “Physiology and philosophy of breeding horses”.  Journal of 
Equine Veterinary Science 19(6):363-373. 
Plotka, E.D., C.W. Foley, et al. (1975).  “Periovulatory changes in peripheral plasma 
progesterone and estrogen concentrations in the mare”. American Journal of Veterinary Research 
36(9):1359-1362. 
Porter, M., B. Cleaver, et al. (1997)a. “The effect of pulsatile gonadotropin-releasing hormone 
and estradiol administration on luteinizing hormone and follicle-stimulating hormone 
concentrations in pituitary stalk-sectioned ovariectomized pony mares”.  Domestic Animal 
Endocrinology 14(5):275-285. 
Porter, M., B. Cleaver, et al. (1997) b. “Comparative study between pony mares and ewes 
evaluating gonadotrophic response to administration of gonadotropin-releasing hormone”.  
Journal of Reproduction and Fertility 110:219-229. 
Porter, M. and D. Sharp (2002). “Gonadotropin-releasing receptor hormone trafficking may 
explain the relative resistance to pituitary desensitization in mares”.  Theriogenology 58:523-
526. 
Pycock, J. (2006). “How to maximize the chances of breeding successfully from the older 
maiden mare.” American Association of Equine Practitioners Proceedings 52: 245-249. 
Roser, J.F., B.L. Kiefer, et al. (1979). “The development of antibodies to human chorionic 
gonadotropin following its repeated injection in the cyclic mare”.  Journal of Reproduction and 
Fertility Supplement 27:173-179. 
Samper J. (1997) “Ultrasonographic appearance and the pattern of uterine edema to time 
ovulation in mares.”  American Association of Equine Practitioners Proceedings 43: 189-91. 
Samper, J, S. Jensen, et al. (2002). “Timing of induction of ovulation in mares treated with 
Ovuplant or Chorulon”.  Journal of Equine Veterinary Science 22(7): 320-23. 
Santos, J.E.P., J.A. Bartolome, et al. (2004) “Effect of a deslorelin implant in a timed artificial 
insemination protocol on follicle development, luteal function and reproductive performances of 
lactating dairy cows”. Theriogenology 61: 412-435.  
Schneider, F., W. Tomek, et al. (2006).  “Gonadotropin-releasing hormone (GnRH) and its 
natural analogues: A review”. Theriogenology 66:691-709. 
94 
 
Shand, N., C.H. Irvine, et al. (2000).  “A detailed study of hormonal profiles in mares at 
luteolysis”. Journal of Reproduction and Fertility Supplement  56: 271-79. 
Sharp, D.C., M.J.Thatcher, et al. (1997).  “Relationship between endometrial oxytocin receptors 
and oxytocin-induced prostaglandin F2 Alpha release during the oestrous cycle and early 
pregnancy in pony mares”.  Journal of Reproduction and Fertility 109:137-44. 
Short, R.V. (1959). “Progesterone in blood. IV. Progesterone in the blood of mares”.  Journal of 
Endocrinology 19:207-210. 
Sieme, H., T. Shafer, et al. (2003). “The effects of different insemination regimes on fertility in 
mares”.  Theriogenology 60: 1153-1164. 
Silvia, P., E. Squires, et al. (1986).  “Changes in the hypothalamic-hypophyseal axis of mares 
associated with seasonal reproductive recrudescence”.  Biology of Reproduction 35: 897-905. 
Squires, E. (2008).  “Hormonal manipulation of the mare”.  Journal of Equine Veterinary 
Science 28(11): 627-634. 
Squires, E.L., J. K. Brubaker, et al. (1998) “Effect of sperm number and frequency of 
insemination on fertility of mares inseminated with cooled semen”. Theriogenology 49:743-749. 
Squires, E.L., P.M. McCue, et al. ((1999). “The current status of equine embryo transfer”. 
Theriogenology 51: 91-104. 
Squires E, Moran D, et al. (1994). “Effect of dose of GnRH analog on ovulation in mares”. 
Theriogenology 41:757-69. 
Squires, E., R. Wallace,  et al. (1981). “The effectiveness of PGF2α, HCG, and GnRH for 
appointment breeding of mares”.  Journal of Equine Veterinary Science 1(1):5-9. 
Stabenfeldt, G., J. Hughes, et al. (1971). “Ovarian activity during the estrous cycle of the mare”. 
Endocrinology 90(5): 1379-1383. 
Stabenfeldt, G., J. Hughes, et al. (1975).  “Unique aspects of the reproductive cycle of the mare”.  
Journal of Reproduction and Fertility Supplement 23:155-160. 
Townsend, D.H., R.A. Pierson, et al. (1989).“Characterization of plasma progesterone 
concentrations for two distinct luteal morphologies in mares”. Theriogenology 32(2):197-204. 
Ursula, B., P. Kaiser, et al. (1997).  “Studies of gonadotropin –releasing hormone (GnRH) action 
using GnRH receptor-expressing pituitary cell lines”.  Endocrine Reviews 18(1):46-70. 
Vanderwall, D.K., T.D.Juergens, et al. (2001).  “Reproductive performance of commercial 
broodmares after induction of ovulation with HCG or Ovuplant™ (deslorelin)”.  Journal of 
Equine Veterinary Science 21(11): 539-542. 
95 
 
Voge, J., A. Sudderth, et al. (2012).  “Comparison of efficacy of two dose rates of histrelin to 
human chorionic gonadotropin for inducing ovulation in broodmares”.  Journal of Equine 
Veterinary Science 32:208-10. 
Volkmann, D.H., M.A. Kutzler, et al. (2006) “Failure of hCG to support luteal function in 
bitches after estrus induction using deslorelin implants”. Theriogenology 66:1502-1506.  
Voss,  J.L., J.J. Sullivan,  et al. (1975). “The effect of HCG on duration of oestrus , ovulation 
time and fertility in mares”.  Journal of Reproduction and Fertility Supplement 23:297-301. 
Watson, E., M. Heald, et al. (2002).  “Plasma FSH, inhibin A and Inhibin isoforms containing 
pro- and –αC during winter anoestrus, spring transition, and the breeding season in mares.” 
Reproduction 123:535-542. 
Witherspoon, D. (1971). “The oestrous cycle of the mare”.  Equine Veterinary Journal 3(3):114-
17. 
Woods, J., D. Bergfelt, et al. (1990).  “Effects of time of insemination relative to ovulation on 
pregnancy rate and embryonic-loss rate in mares”.  Equine Veterinary Journal 22(6): 410-415. 
Yoon, M., I. Bolme, et al. (2007). “The efficacy of a single chain recombinant equine luteinizing 
hormone (reLH) in mares: Induction of ovulation, hormone profiles, and inter-ovulatory period”.  
Domestic Animal Endocrinology 33(4): 470-479.  
  
96 
 
APPENDIX A: 
 
Association of ovulation induction and the number of palpations performed per cycle for all 
mares in the study and the subset of mares becoming pregnant: 
 
Results for all mares in the study: 
The results for the inclusive group of  mares in the study showed that mean number of 
palpations for all mares, pregnant or non-pregnant, across the 3 treatment groups had a 
statistically significant association with treatment (F=47.033, p=0.000, r
2
=.231) (table follows).  
Potential confounders were introduced into the model: mare, number of AIs, size of follicle at 
treatment, day of ovulation and pregnancy (r
2
=.634, F=286.326, p= 0.000).   Treatment group 
and all of these covariates except mare were significantly associated with the mean number of 
palpations (p<0.001).  After adjusting for the set of covariates, at least one of the mean numbers 
of palpations was determined to be significantly different from the other treatment groups. Post 
hoc pairwise comparison (Table 7ii) indicated that the mean number of palpations for mares 
receiving deslorelin (3.5) was significantly higher than for those receiving hCG (2.9) or those in 
the Control group (3.2)(p=.000).  There was no significant difference between those receiving 
hCG and those in the Control group (p=.000).  The median number of palpations for all the 
agents was 3.00. 
 
Results for the subset of mares which become pregnant on the induced cycle: 
A significant association between treatment group and the number of palpations received per 
cycle for mares becoming pregnant was determined (F= 45.845, p=0.000,  r
2
=.087) . Controlling 
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for mare, number of AI, size at treatment, day of ovulation and pregnancy proved statistically 
significant (p<0.001,  r
2
 =.063) .  Treatment group and all of the covariates except mare were 
significantly associated with the mean number of palpations (p< 0.001) for pregnant mares.  
Adjusting for the set of covariates supported the conclusion that at least one of the mean numbers 
of palpations for mares becoming pregnant was significantly different. (p=.000).   
Reducing the number of palpations per cycle would have labor and financial advantages 
for the owner, farm manager, and veterinarian.  In this study we did not note a significant 
decrease in the overall number of palpations performed on the mares after inducing ovulation.  
The use of deslorelin was actually associated with a significant increase in the number of 
palpations when compared to hCG and untreated mares.  The increase in palpations is most 
likely related to its high rate of use on Farm 2, which managed a higher number of shipped 
chilled semen, embryo donor, and subfertile mares.  Such mares require closer monitoring of the 
uterine environment during breeding, fewer inseminations, and insemination closer to ovulation 
to improve pregnancy rates. (Crowe, et al, 2008; Sieme, et al, 2003; Pycock, 2006)  No studies 
were found that looked at the effect of ovulation induction on the number of palpations 
performed. 
The result of a higher number of palpations is not unreasonable.  Mares being managed 
for chilled semen or frozen semen inseminations will require more frequent palpations to ensure 
timely arrival of the semen and an appropriately timed insemination to improve the odds of 
conception.  Mares which are of poor fertility secondary to age or uterine pathology may require 
frequent palpation to not only ensure optimal timing of insemination but to also reduce the 
amount of semen placed in the tract (to reduced post mating inflammation of the endometrium 
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and improve the post mating uterine environment). Poor stallion fertility may also create a 
situation in which mares must be managed to reduce the number of breeding’s they receive.  
Hence it may be concluded that ovulation induction may not reduce the number of 
palpations in certain circumstances where timing of insemination and ovulation are essential.   
Tables:   
One-Way ANOVA comparing the mean number of palpations for all mares across the 
three treatment groups ( hCG, deslorelin, and no treatment )  
ANOVA
a
 
 Sum of Squares Mean Square F value P Value 
Regression 78.286 78.286 47.033 .000b 
Residual 1468.129 1.664   
Total 210.266 
 
   
a. Dependent variable: Palpations  
b. Predictor:  Treatment (p=.000) 
c. r
2
=.231 
 
Multivariable Regression Model comparing the mean number of palpations for all mares 
across the three treatment groups, controlling for: Mare, Number of AIs, Size at 
Treatment, Day of Ovulation and Pregnancy 
ANOVA
a
 
 Sum of Squares Mean Square F value P Value 
Regression 930.116 186.023 287.326 .000
b
 
Residual 538.013 .647   
Total 1468.129    
a. Dependent variable: Palpations 
b. Predictor:  Days to Ovulation, Mare, Size at Treatment, Treatment, AI 
c. r
2
=.634 
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Coefficients
a
: 
 T Value P value 
Treatment 
AI 
Size at treatment 
Mare 
Days to Ovulation 
9.033 
3.542 
-4.249 
-.858 
27.832 
.000 
.000 
.000 
.391 
.000 
 
(Dependent Variable: Palpations) 
 
Post Hoc Comparisons (Wilcoxon Signed Ranks Test) for Mean Number of Palpations for 
Mares Receiving Ovuplant™(PO), Mares Receiving hCG(PH), and Mares Receiving No 
Treatment(PN). 
 
 PO-PH PN-PH PO-PN 
Z Value -6.037
a
 -0.795 -6.710
a
 
Asymp. Sig. (2 tailed) 0.000 0.427 0.000 
 
Based on negative ranks. 
 
One-Way ANOVA comparing the mean number of palpations for pregnant mares across 
the three treatment groups (hCG, deslorelin, and no treatment) 
ANOVA
a 
 Sum of Squares Mean Square F value P Value 
Regression 69.759 69.759 45.845 .000
b
 
Residual 712.122 1.552   
Total 781.881    
a. Dependent variable: Palpations  
b. Predictor:  Treatment 
Coefficients
a
: 
 T Value P value 
Treatment -6.771 .000 
a. Dependent Variable: Palpations 
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Multivariable Regression Model comparing the mean number of palpations for pregnant 
mares across the treatment groups controlling for: Mare, Number of AIs, Follicle Size at 
Treatment, Day of Ovulation and Pregnancy. 
ANOVA
a
 
 Sum of Squares Mean Square F value P Value 
Regression 495.962 99.192  .000
b
 
Residual 285.919 .616   
Total 781.881    
a. Dependent variable: Palpations 
b. Predictor:  Days to Ovulation, Size at Treatment, Mare, Treatment, AI 
Coefficients
a
: 
 T Value P value 
Treatment 
Mare 
AI 
Size at treatment 
Days to ovulation 
-7.165 
-.102 
4.557 
-2.609 
20.345 
.000 
.919 
.000 
.009 
.000 
 
a. Dependent Variable: Palpations 
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APPENDIX B: 
 
Association of ovulation induction and the number of artificial inseminations performed per 
cycle for all mares in the study and the subset of mares becoming pregnant: 
 
ANOVA did not show a significance of treatment with the number of artificial 
inseminations.  A comparison between treatments using multivariable regression introducing the 
potential effects of mare, number of palpations, size of follicle at treatment, day of ovulation and 
pregnancy was attempted and found significance of treatment(p=.000; r
2
=.303).  A Wilcoxon-
Signed Ranks test for post hoc pairwise comparison found that the mean number of AI for mares 
receiving deslorelin (1.19±.024) and those not treated was significantly lower than for those 
receiving hCG (1.59±.045).  There was no difference between mares treated with deslorelin and 
those not induced to ovulate (1.21±.044) (p=.000).  The individual mare was found to not be 
significantly associated with the mean number of AI.  Although this model showed significance, 
other variables could be introduced into the model.  Since ANOVA did not prove a significance 
of treatment, model fit could be improved before drawing conclusions on this association.   
For mares that became pregnant, treatment was shown to be significantly associated with 
the number of AIs by multivariable regression analysis controlling for mare, number of 
palpations, size at treatment, and day of ovulation (p=0.000).  Results however were similar to 
the inclusive set of mares and did not show a difference between mares induced to ovulate and 
untreated mares.   Only a difference between mares treated with deslorelin and hCG treated 
mares was determined.  Treatment, days to ovulation (DaysO) and number of palpations, were 
significantly associated with the mean number of AI (p<0.001) in this model.  Unlike for all 
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mares, pregnant or not pregnant, the size of the follicle at treatment was not significantly 
associated with the number of AI for mares becoming pregnant.   
Multivariable regression analysis performed on the inclusive group of mares found an 
effect of treatment (p=.000) along with several other variables.  Pairwise comparison testing 
determined there was a decrease in the number of artificial inseminations on mares induced to 
ovulate with deslorelin but not hCG.  This same relationship was detected in the pregnant mares 
also.  Finding that deslorelin performed better than hCG at reducing the number of artificial 
inseminations agrees with both a large retrospective study (Allen, 2007) and a controlled study 
(Jochle, et al, 1994).  This outcome may be driven by the fact that deslorelin has been shown to 
have a more consistent and reliable rate of ovulation induction than hCG. (Samper et al, 2002) 
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Multivariable Regression Model comparing the mean number of AIs across the three 
treatment groups for all mares, controlling for: Mare, Number of Palpations, Size at 
Treatment, Day of Ovulation and Pregnancy. (r2=.303) 
ANOVA: 
 Sum of Squares Mean Square  F Value P Value 
Regression 330.623 55.104 99.367 0.000 
Residual 761.392 0.555   
Total 1092.014    
Coefficients: 
 
 
T Value 
 
P value 
Treatment -2.640 .008 
Mare 0.500 0.617 
Palpations 2.741 0.006 
Size at Treatment 10.925 0.000 
Days to Ovulation 11.203 0.000 
Pregnancy 5.263 0.000 
 
Wilcoxon Signed Ranks Test comparing the mean number of AI for mares receiving 
treatment with deslorelin (Ovuplant™, PO), hCG (PH), and no treatment (PN) 
 PO-PH PN-PH PO-PN 
Z Value -12.410
a
 -0.129
a
 -2.163
a
 
Asymp. Sig. (2 tailed) 0.000 0.897 0.031 
a
 Sign Test; based on negative ranks. 
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Multivariable Regression Model comparing the mean number of AIs across the three 
treatment groups for pregnant mares only, controlling for: Mare, Number of 
Palpations, Size at Treatment, Day of Ovulation and Pregnancy. 
ANOVA
a
 
 Sum of Squares Mean Square F value P Value 
Regression 66.069 13.214 42.520 .000
b
 
Residual 144.197 .311   
Total 210.266    
a. Dependent variable: AI 
b. Predictors:  Palpations, Mare, Size at Treatment, Treatment, Days to Ovulation 
c. r
2
=.314 
Coefficients
a
: 
 T Value P value 
Treatment 7.630 .000 
Mare .259 .796 
Palpations 4.557 .000 
Size at Treatment 1.536 .125 
Days to Ovulation 4.473 .000 
 
Dependent Variable: AI 
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APPENDIX C: 
 
Effect of ovulation induction on the length of estrus: 
When the overall length of estrus was examined for mares treated and compared to mares not 
treated, ovulation induction did not consistently shorten the estrus interval.  At smaller follicle 
sizes there is a trend toward the ovulation inductions creating a shorter estrus period.  At larger 
follicle sizes, over 40mm in diameter, the mares not induced to ovulate proved to have a shorter 
period to ovulation than the mares treated.  To determine if this effect is real, several factors 
would need to be examined and controlled for such as time of year the mares were examined, the 
individual cycles of the mares, and reproductive management of the mares.  There can be much 
individual variation in the length of estrus among mares. (Stabenfeldt et al, 1975; Adams, et al, 
1988; Witherspoon, 1971; Ginther, et al, 1972; Hughes, 1980)  Season of the year affects estrus 
length do to photoperiod variation.   (Adams, 1988; Ginther, et al, 1974; Hughes, et a, 1977)  
One farm used teasing as a staging method and may not have observed mares until teasing was 
noted.  Hence, a more precise way to determine the first day of estrus and more frequent 
palpations would improve accuracy.  More frequent palpations would benefit to know the exact 
beginning of estrus also. 
At follicles 35-39 mm in diameter, the deslorelin treated mares and mares not induced to ovulate 
had comparable average days to estrus while hCG treated mares appeared to have a slightly 
shorter period of days to ovulation as expected with ovulation induction.  Management of the 
mares would most likely account for these varying results as Farm 2 managed more chilled 
semen and infertile mares.  Farm 2 also used more of the slow release implants, Ovuplant™. 
Sensitive mares treated with Ovuplant™, which can effect return to estrus and the ability to 
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evaluate a mare for the return to estrus.  Mares treated with Ovuplant on the previous estrus have 
decreased levels of FSH and hence produce a smaller dominant follicle (i.e. a smaller follicle at 
ovulation) and will display less endometrial edema. This leads to a later average ovulation date 
in comparison to non-treated, non-sensitive mares.  (Vanderwall, et al, 2001; Morehead, et al, 
2000; Johnson, et al, 2000)  In this study, interovulatory period was not specifically examined so 
the effect of sensitive mares is unknown.   
In order to determine the effect ovulation had on the overall length of estrus, a controlled study 
will need performed and more frequent palpations required. 
Histogram:  An analysis of the mean number of days from the first day of estrus to 
ovulation for mares treated with hCG, for mares treated with deslorelin, and for mares not 
treated. 
 
1
P value:  35-39mm=.010; 40-44mm=.001; >45mm=.003 
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